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Riassunto 
 
 La sub-fertilità rappresenta uno dei principali problemi che l’industria lattiero-
casearia si trova ad affrontare attualmente. Si tratta di un problema multifattoriale che 
dipende da diversi aspetti della funzione riproduttiva. La qualità dell’ovocita, 
determinata durante la follicologenesi, è sicuramente cruciale per ottenere risultati 
riproduttivi ottimali. Per migliorare la fertilità femminile nel bovino è fondamentale 
definire i fattori e i meccanismi che determinano la qualità del gamete femminile, in 
quanto il declino della funzione riproduttiva in questa specie è dovuto principalmente 
alla scarsa qualità degli ovociti. In particolare, è importante conoscere quali proteine 
regolano la meiosi, la fecondabilità e lo sviluppo embrionale dell’ovocita. In questo 
progetto, abbiamo considerato principalmente il ruolo del Progesterone Receptor 
Membrane Component-1 (PGRMC1) sia nell’ovocita che nel compartimento follicolare, 
considerato che il dialogo tra compartimento germinale e compartimento somatico è 
uno dei fattori chiave coinvolti nell’acquisizione della competenza allo sviluppo del 
gamete femminile. 
 Il PGRMC1 è una proteina multifunzionale ed altamente conservata in specie 
anche filogeneticamente distanti. Nei mammiferi è espressa in diversi sistemi, 
compresi gli organi riproduttivi, e localizza in diversi compartimenti subcellulari. 
Tuttavia, il suo ruolo e il preciso meccanismo d’azione in ogni sistema e/o 
compartimento subcellulare non sono ancora del tutto conosciuti.  
La parte più considerevole di questo progetto di dottorato riguarda gli studi effettuati 
sul ruolo del PGRMC1 nella divisione cellulare, data la sua localizzazione a livello di 
fuso mitotico e meiotico. Abbiamo dimostrato che la deplezione del PGRMC1 
determina difetti nella divisione cellulare e la sua interazione con l’Aurora chinasi B 
(AURKB) indica che potrebbe svolgere la sua azione durante la citodieresi, l’ultima 
fase della divisione. Durante la maturazione meiotica, abbiamo valutato anche il suo 
ruolo nel mediare l’azione del progesterone (P4) confrontando il suo effetto con quello 
del recettore nucleare del progesterone (nPGR). L’inibizione di entrambi i tipi di 
recettore determina lo stesso effetto sull’organizzazione della piastra metafasica e 
sulla competenza allo sviluppo dell’ovocita, ma in fasi differenti.  
 Inoltre, abbiamo testato l’ipotesi che il PGRMC1 possa modulare la funzione del 
nucleolo. Studi di immunofluorescenza hanno confermato la presenza del PGRMC1 
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nel nucleolo di cellule della granulosa (bGC) e negli ovociti di bovino, nonchè la 
colocalizzazione con la nucleolina, la proteina nucleolare più abbondante che svolge 
importanti funzioni in questo compartimento subcellulare. Inoltre, la down-regolazione 
del PGRMC1 determina uno spostamento della nucleolina dal nucleolo al 
nucleoplasma suggerendo un’associazione funzionale tra queste due proteine. Questa 
interazione è probabilmente mediata dalla presenza di ulteriori molecole in quanto 
successivi esperimenti di “in-situ proximity ligation” mostrano che le due proteine non 
interagiscono direttamente.  
 Oltre al tema principale di questo progetto, la divisione cellulare è uno dei 
processi più importanti anche nel cancro e l’espressione del PGRMC1 è elevata in 
molti tipi di tumore nell’uomo. Per questo abbiamo intrapreso uno studio preliminare 
per caratterizzare la sua espressione nei diversi tipi di tumore mammario di cane. In 
base ai nostri risultati, l’espressione del PGRMC1 diminuisce con l’aumentare della 
malignità del tumore e le diverse isoforme di PGRMC1 sono presenti sia nel tessuto 
sano che in quello neoplastico.  
 In conclusione, i nostri risultati suggeriscono che il PGRMC1 può avere un ruolo 
nel compartimento follicolare, in particolare sia nella mitosi che nella meiosi. La sua 
funzione potrebbe essere legata alla sua localizzazione nucleolare, nonchè alla sua 
capacità di mediare l’azione del P4 durante la meiosi dell’ovocita. Il suo ruolo come 
regolatore della divisione cellulare può essere rilevante anche in alcune patologie quali 
il cancro. Ulteriori studi saranno diretti a valutare i meccanismi di azione molecolari 
tramite i quali il PGRMC1 agisce in questi processi al fine di ampliare la nostra 
conoscenza di questa proteina poliedrica.  
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Abstract 
 
Subfertility is one of the major problems that dairy industry is facing nowadays. 
Subfertility is a multifactorial issue depending on different aspects of reproductive 
function. Oocyte quality, which is determined during folliculogenesis, is certainly crucial 
for optimal reproductive outcome. Since declining fertility of cattle is mainly due to the 
poor quality of the oocytes, defining the factors and mechanisms that affect oocyte 
quality is essential to improve female fertility. In particular, basic knowledge of which 
proteins within the oocyte regulate meiosis, oocyte fertilizability and early embryonic 
development would be advantageous. In this project, we primarily considered the role 
of Progesterone Receptor Membrane Component-1 (PGRMC1) in both the oocyte and 
follicular compartment since the dialogue between the two compartments is one of the 
key factors involved in oocyte competence acquisition. 
 PGRMC1 is a highly conserved and multifunctional protein that is found 
expressed in multiple systems, including reproductive organs, and localizes in multiple 
sub-cellular compartments. However, its role(s) and precise mechanism(s) of action in 
each systems and/or subcellular compartment are not yet fully understood. 
 The more considerable part of this PhD project consists of studies on 
PGRMC1’s involvement as a cell division regulator, according to its localization to the 
mitotic and meiotic spindle.  We showed that PGRMC1 depletion leads to defective 
cell division in both oocyte and somatic cells and its action could be exerted during 
cytokinesis, the very last mitotic phase, as demonstrated by its association with Aurora 
kinase B (AURKB). During meiotic maturation, we also evaluated PGRMC1 
involvement as a possible mediator of progesterone (P4) action, by comparing the 
effects of inhibiting its function with that of nuclear progesterone receptor’s (nPGR) 
inhibition. Our data suggests that both receptors have an effect on meiotic progression 
but possibly at different stages of oocyte maturation. 
 Moreover, we tested the hypothesis that PGRMC1 might modulate the function 
of the nucleolus. Immunofluorescence experiments confirmed PGRMC1 nucleolar 
localization in bovine granulosa cells (bGC) and bovine oocytes and its co-localization 
with nucleolin, the most abundant nucleolar protein exerting important functions in this 
subcellular compartment. Moreover, a PGRMC1/nucleolin functional association is 
suggested by PGRMC1’s downregulation determining nucleolin shift from the 
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nucleolus to the nucleoplasm. However, in situ proximity ligation assay did not detect 
a direct interaction between these two proteins, suggesting the involvement of 
additional molecules that could mediate PGRMC1/nucleolin interaction.  
 Besides the main theme of this project, cell division is one of the most important 
processes in cancer biology and PGRMC1 is known to be overexpressed in many 
types of tumors in humans. Therefore, we studied its expression in different types of 
canine mammary tumors. Our preliminary results showed PGRMC1 expression 
decreases with the malignancy of the tumor and different PGRMC1 isoforms are 
present both in normal and tumoral tissue.  
 To conclude, these findings suggest a role of PGRMC1 in the follicular 
compartment, being implicated in both meiotic and mitotic process of the germinal and 
somatic compartment, respectively. This action it is likely mediated by PGRMC1 
located at a particular site of the spindle, i.e the midzone and /or the midbody of dividing 
cells. PGRMC1 also localizes at the nucleolus of both oocytes and granulosa cells 
where it likely exerts additional function(s) in mediating cellular stress and/or other 
nucleolar-relates process. Clearly these findings have major implication in the overall 
process of folliculogenesis. Moreover, PGRMC1’s role as a regulator of cell 
proliferation could be relevant also in some diseases such as cancer. Further 
investigations will aim at investigating PGRMC1’s molecular mechanisms of action in 
these processes to widen our knowledge on this multifaceted protein.  
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Foreword 
 
 
This thesis is structured as follows. 
 The introduction consists of a wide overview about the infertility issue that is 
being faced by dairy industry nowadays, which has several implications at economical 
level and animal welfare. Infertility is a multifactorial problem and among the numerous 
factors that could be involved, we propose Progesterone Receptor Membrane 
Component-1 (PGRMC1) as one of the putative key factors. Therefore, introduction is 
followed by a state of the art about PGRMC1 focusing on its role in reproductive 
function.  
 The subsequent chapters represent the four different parts of this research 
project and each section is structured as a paper, each with its own bibliography at the 
end.  
Chapter 5 and 7 are published papers. Chapter 6 describes results of a project shared 
with Prof. Trudee Fair, which were in part achieved during my PhD visiting period at 
University College of Dublin. Chapter 8 shows preliminary results obtained on 
PGRMC1 in canine mammary tumors that are to be submitted for publication. The 
original published papers of chapter 5 and 7 can be found in the appendix. 
 To conclude, a general discussion and future perspectives are shown to 
summarize and relate results from different PGRMC1 aspects studied during my PhD 
program.  
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Introduction 
 
 
1. The contemporary issue of subfertility affecting dairy cows 
 
 
 Cow subfertility is one of the main problems that is being faced by dairy industry 
nowadays. Dairy cow lactation cycle and, therefore, milk production depends on 
female’s ability to become pregnant and, therefore, fertility is one of the most important 
parameter to understand and improve in order to achieve high production rate [1].  
 Over the last 50 years there is evidence of a constant decline in worldwide dairy 
cow fertility, which could be expressed in different ways such as pregnancy rates to 
first insemination [2], calving interval, duration from calving to conception or number of 
insemination for conception [3]. Subfertility is defined as any condition leading to failure 
to establish a pregnancy following completion of uterine involution at 40–50 days post-
partum [4]; being the major cause for culling animals it has a great impact on dairy 
economics. In addition, the lost income from milk sale, the cost of semen needed for 
repeated attempts to artificially inseminate cows and the replacement of culled animals 
are all factors contributing to economic loss. Furthermore, it also has obvious animal 
welfare implications [4].  
 High selection to achieve increased milk yields has been considered to 
negatively impact on reproductive efficiency. However, higher milk production does not 
seem to be the unique feature to blame and physiological adaptations to high milk 
production may explain only part of the reproductive decline [1]; indeed, some of the 
highest milk productive herds do not show poor reproductive efficiency maybe due to 
the better feeding, health and reproductive management [5, 6]. 
 Hence, it is evident that subfertility is a complex and multifactorial issue; the 
exact reason for its decline is still not clear, but it is determined by a combination of 
genetic, physiological, environmental and managerial factors [1]. 
 The main factors affecting fertility during dairy cow stages of reproductive life 
are shortly mentioned below and summarized in Figure 1.1. 
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Figure 1.1 From [7]. Summary of various aspects involved in the establishment of a 
pregnancy in dairy cows. 
 
 
1.1 Genetics, management and pre-partum period  
 
 During the last 30 years, genetic selection for increased milk production has 
been successfully conducted, in particular in the Holstein Friesian genotype. This is 
accompanied by a decrease in reproductive efficiency. However, the initial negative 
association between these two parameters has recently been reviewed and other 
factors are considered to be involved in subfertility besides genetic alone [7]. 
 Poor management of dairy cows plays an essential role in reducing fertility, 
together with poor nutrition and environmental factors, which are all factors often not 
evaluated in studies considering only the genetic effect [8]. For example, reproductive 
management has to be adapted to new conditions such as bigger herd size which has 
impact on heat detection methods and on the incidence of some reproductive diseases 
(uterine and mammary infections) due to increased use of confinement houses, which 
affect reproductive efficiency [9, 10]. 
 Moreover, also changing in global environment leading to heat stress could be 
partially a risk factor influencing fertility. Indeed, heat stressed animals may have 
extended interval from calving to first ovulation due to low lutenizing hormone (LH) 
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pulse amplitude and frequency, smaller dominant follicles and low oestradiol 
concentrations [11]. 
 In addition, some production diseases that are caused by poor/incorrect 
management such as undernutrition, hypocalcaemia, mastitis or lameness are linked 
to reduced reproductive performance [7]. Nutritional and health status during 
productive cycle is visually monitored using the subjective parameter of body condition 
score (BCS) [12]. Energy requirements in high milk producing cows dramatically 
increases due to high daily milk yield, which peaks between 4 and 8 weeks post-
partum. At the same time, the cow feed intake is reduced (limitations in the intake and 
less appetite) and inadequate to meet her maintenance and production requirements. 
Consequently, body reserves are mobilized and the animal enters negative energy 
balance (NEB). [13].  
 When NEB becomes severe, there is an increased risk of metabolic diseases, 
especially within the first month of lactation [12]. The most common metabolic diseases 
that could affect cows are acidosis, fatty liver disease, retained placenta and displaced 
abomasum, hypocalcaemia, hypomagnesaemia and ketosis. [14, 15].  
 NEB condition leads to elevated free fatty acid (NEFA) concentrations in 
maternal blood and this could alter follicular microenvironment. Several in vitro studies 
in bovine and murine models showed that especially long-term exposure to NEFAs 
impaired ovarian follicles growth and, consequently, reduced oocyte’s developmental 
competence [16]. Blastocysts developing from these oocytes are characterized by a 
significant lower cell number and increased apoptotic cell index [17] and also their 
transcriptome and epigenome signature are altered [18, 19].  
 Moreover, metabolic changes in mothers negatively affect in vitro bovine oviduct 
epithelial cells; the oviduct likely modulate its microenvironment to safeguard the 
embryo from toxic metabolites, but in vivo the regulation of the oviduct embryonic 
milieu is not assured in females with metabolic disorders thus reducing embryo 
development and quality [20].  
 Finally, exposure to NEFAs during oocyte maturation may have long lasting 
effects influencing the later peri-implantation period, which is a very critical moment for 
the establishment of the pregnancy. Indeed, in vitro produced embryos exposed to 
NEFA and transferred to recipient cows were less developed and metabolically 
compromised when recovered after 7 days [21].  
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 The above mentioned metabolic disorders could also worsen the physiological 
low degree of immunodeficiency during early lactation and increase the incidence of 
pathologies such as: metritis, mastitis, lameness [14]. At parturition, bacteria normally 
contaminate the uterus and the majority of the cows successfully deal with the most 
common pathogens. However, few animals develop metritis within 21 days post-
partum [22]. Clinical mastitis incidence is increased by reduced immune competence 
predisposing to the invasion of pathogens causing this infection. In animals affected 
by acidosis the release of endotoxins and histamine from the rumen destroy the 
microvasculature of the corium causing laminitis and consequent lameness; the same 
metabolites act at a neuroendocrine and ovarian level. It is clear that all these 
pathologies in the early post-partum have a detrimental effect on the subsequent 
fertility success of the animal, impairing different stages of reproduction Good 
management of the animals could improve the control of such adverse effects [1, 7]. 
 
 
1.2 Breeding season and insemination 
 
 In order to achieve a 365-day calving interval the breeding season should start 
60 days postpartum and the establishment of the pregnancy should happen by 83 days 
postpartum, assuming a 282 days gestation length. Therefore, by this time all early 
post-partum/pre-partum disorders and diseases must resolve and the resumption of 
the normal oestrus cycle is essential for a cow to become pregnant again [7]. 
 Up to 50% of modern dairy cows have abnormal oestrus cycles postpartum with 
a consequent increase in calving to first insemination interval and decreased 
conception rates [23]. Several risk factors have been identified for this delayed first 
ovulation and they include greater NEB in primiparous cows than multiparous cows [1]. 
 Severe NEB together with low BCS reduce pulsatile LH secretion, ovarian 
responsiveness to LH and oestradiol production from the follicle, delaying ovulation 
[24]. Moreover, periparturient disorders, season of calving, wrong management and 
diseases listed above are all factors impairing the resumption of ovulation [23, 25]. 
 In order to inseminate cows at the correct time of ovulation, together with the 
resumption of cyclicity overt signs of oestrus must be clearly present. Over the past 50 
years the duration and the intensity of detected oestrus has reduced [26]. Poor 
expression of oestrous behaviour renders it less easy to be visually detected, but 
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luckily there are methods such as pedometers assuring 80-100% of oestrus detection 
rate [1]. Risk factors for poor expression are both cow-specific (silent/anovulatory 
anoestrus, parity, milk production, health) or environmental-related (nutrition, housing, 
season, number of mates simultaneously in oestrus) [27]. 
 Clearly, one of the most important factors to ensure optimal ovulation rates is a 
correct folliculogenesis, which is extensively dealt with in the next chapter. Ovarian 
follicle development also affects fertilization success and the consequent 
establishment of pregnancy. 
 
 
1.3 Fertilization, embryo development and pregnancy 
 
 Assuming that all possible issues and paraphysiological statuses of post-partum 
are resolved or absent and that fertilization is done at the correct timing with the 
appropriate technique, reproductive failure could depend on other two major factors: 
fertilization failure and embryonic mortality/poor embryo survival after fertilization [3, 
7]. 
 High fertilization failure is observed especially in high producing cows with 
fertilization rates dropping from 95% to 83% during the last 40 years [28]. Fertilization 
and the consequent development of a viable embryo depend on the intrinsic quality of 
the two gametes; the oocyte and the sperm. Sperm characteristic affecting fertilization 
are: viability, morphology and functional and molecular traits, inability to reach the site 
of fertilization, to penetrate the oocyte, to prevent polyspermy or to initiate fertilization 
itself. When fertilization is achieved through artificial insemination, also technicians 
performing the procedure could impact the fertilization rate [29].  
 Heat stress, physiological status (lactating and non-lactating) and factors listed 
previously such as diseases or metabolic disorders could affect oocyte quality during 
follicle development and have detrimental effects on the female gamete also after 
months from the insult [7, 30]. Oocyte quality is poorly defined and is strictly dependent 
on the follicle, which represents its developmental niche; a wider discussion on this 
topic is made in the next chapter. 
 In Holstein dairy cows, also calving rates have declined and are close to 35-
40% [1]. After fertilization of the oocyte in the oviduct, the resulting embryo undergoing 
the first mitotic cleavage divisions is transported towards the uterus, where it reaches 
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the 16-cell stage at day 4 of pregnancy. Then it becomes a morula, a compact ball of 
cells and at day 7 of pregnancy it forms a blastocyst characterized by an inner cell 
mass, which will form the embryo, while the placenta will rise from the trophectoderm. 
Until this stage the embryo is almost autonomous and the contact with maternal 
reproductive tract is not mandatory, but already affects its quality [3]. On days 9 to 10 
the blastocysts undergo hatching from the zona pellucida and its morphology changes 
from spherical to a final filamentous form on days 16-17 that occupies one of the 
uterine horns; here the elongated conceptus begins implantation on the endometrium 
[31]. Post-hatching the interaction between the conceptus and endometrium is 
essential for the conceptus development and the establishment of the pregnancy. 
Thus, a healthy endometrium and its correct function are essential [32]. 
 Embryo mortality can happen in three periods. Very early mortality occurs 
between days 0 and 7, early mortality between days 7 and 24 and late mortality from 
days 24 to 45. After day 45 it is considered fetal mortality. The majority of embryonic 
mortality occurs within 3 weeks of gestation (early embryonic mortality) [7, 33]. Very 
early embryo mortality is mainly due to poor oocyte quality [34] or suboptimal uterine 
environment [35]. Moreover, an early rise in progesterone between days 4 and 7 after 
insemination alters endometrial secretions that stimulates embryo development after 
day 7, leading to larger embryos more prone to stimulate maternal recognition of 
pregnancy [33]. 
 Also during early embryo mortality uterine microenvironment and function 
together with inadequate levels of circulating progesterone are risk factors leading to 
failure of maternal recognition of the conceptus and mortality [7]. 
 Late embryo and fetal mortality are due to genetic, physiological, 
endocrinological, environmental factors and pathogenic agents [33, 36]. 
 
 
1.4 Oocyte quality 
 
 In mammalian fertility, the good quality of the female gamete is essential to have 
a successful reproductive outcome. As already mentioned, oocyte quality is poorly 
defined but is commonly expressed as the oocyte capability to complete meiosis 
(meiotic competence), being fertilized (fertilization competence) and develop into a 
viable preimplantation embryo (embryonic developmental competence), either in vivo 
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or following in vitro embryo production (IVP) procedure. While the spermatozoon 
makes a complementary genetic contribution to the zygote, the oocyte is obviously the 
major cytoplasmic donor, contributing nearly all the organelles and nonchromosomal 
molecules needed for early embryonic development, up to the stage in which 
embryonic genome if activated. The oocyte grows and differentiates within the ovarian 
follicle; thus, folliculogenesis is the process leading to oocyte growth, maturation and 
ovulation, therefore determining also its quality [37].  
 The criteria to evaluate oocyte quality comprise morphological and 
cellular/molecular predictors (reviewed in [38]) which are continuously under 
investigation to find the most objective and noninvasive ones to be used in different 
species.   
 Morphological parameters include scoring system and classification of cumulus-
oocyte complexes (COCs) evaluating compactness of the cumulus investment and 
ooplasm characteristics [39]. Moreover, data in humans suggest that evaluation of 
polar bodies (PB) morphology and meiotic spindle characteristics such as its presence, 
location and length, which are essential for chromosome alignment and segregation in 
meiosis, can be used in living oocytes to predict oocyte developmental competence 
[40, 41]. 
 While intrinsic predictors, which could be evaluated with more invasive 
techniques, include the activity and the organization of mitochondria, essential for 
cytoplasmic maturation, or glucose-6-phosphate dehydrogenase (G6PDH) activity 
which is associated with high rate of fertilization when it is low in mature oocyte [42, 
43].  
 Finally, follicular fluid and serum components would represent the most suitable 
non-invasive predictors to be used. Some examples of these extrinsic factors are 
steroid hormones, the transforming growth factor (TGF)-β superfamily and insulin-like 
growth factors (IGFs) and their ligands, controlling cellular proliferation and 
differentiation [44-46]. Evaluation of the presence/concentration of these molecules 
would aid indirect assessment of oocyte quality. As already stated above, follicular 
cells and especially cumulus cells are regulator of oocyte development, maturation and 
fertilization and are currently subjects of considerable research as a possible source 
of material to be used to non-invasively assess oocyte quality. 
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 In conclusion, multiple factors are involved in fertility decline of dairy cows and 
there is still a lot to investigate to resolve this issue. On the other hand, correct 
management of the animals including a correct nutrition, efforts to limit known risk 
factors at different stages of reproduction and developing strategies in order to 
enhance fertility such as improving genetic selection, ameliorating oocyte quality and 
in vitro embryo production together with basic research on reproductive physiology 
could all hopefully invert this negative trend.  
 
 In this project, we have focused our studies in the folliculogenesis process that 
is fundamental for the production and ovulation of a good quality female gamete, on 
which depend the subsequent reproductive steps to achieve a viable calf. Oocyte 
quality and key factors affecting it are still poorly understood and, therefore, our aim is 
to investigate on this topic. 
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2. Oogenesis is deeply rooted in folliculogenesis  
 
 
 The lifelong relationship between the oocyte and follicular cells starts very early 
during fetal development of an individual. Prymordial germ cells (PGC) are the 
embryonic precursor of the female gametes, they are located outside the embryo, in 
the yolk sac, and migrate along the hindgut reaching the genital ridge [47, 48]. When 
PGC reach the ovary they start undergoing mitosis, increasing in number and are 
called oogonia [49]. Oogonia switch from mitotic to meiotic division, replicating their 
DNA, thus becoming primary oocytes. During fetal life DNA is exchanged between 
homologous chromosomes through homologous recombination. This process is critical 
for pairing between homologous chromosomes. The paired and replicated 
chromosomes are called bivalents or tetrads, which have two chromosomes and four 
chromatids, with one chromosome coming from each parent. 
 Meanwhile, primordial flattened granulosa cells start surrounding some of these 
oocytes hence forming primordial follicles. The transition from a mitotic to a meiotic 
program is regulated by signals from somatic cells [50, 51]. The origin of granulosa 
cells is still not clear and they could derive from mesonephros and/or from the coelomic 
epithelium [52] or from the mesenchyme of the ovary [53].	
 In the primordial follicle, the oocyte continues its meiotic division going through 
the longest meiotic phase, that is prophase I, undergoing leptotene, zygotene, 
pachytene stages and finally arrests at diplotene (or dictyate) stage until puberty. 
These meiotic arrested oocytes represent the definite pool of oocytes of an individual 
and wait to be recruited for development, that could happen months or even years later 
[49, 54]. After puberty, few of the arrested primordial follicles at a time enter the 
nonreversible growing phase during which granulosa cells become cuboidal and 
restart to proliferate. 
 The growing follicles pass through the stages of primary and secondary follicles, 
characterized by the presence of two layers of granulosa cells, the initial deposition of 
zona pellucida (ZP) material around the oocyte and the beginning of theca cell layer 
formation. When the secondary follicle becomes finally a tertiary follicle, two types of 
granulosa cells differentiate:	mural granulosa cells, lining the follicle wall and cumulus 
granulosa cells, surrounding the oocyte and forming the cumulus cell-oocyte complex 
(COC). Moreover, an antral cavity with follicular fluid forms among these cells. Finally, 
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the outer part of the follicle is delimited by layers of interstitial cells that differentiates 
into internal and external theca cell [55-57]. 
 During follicular growth the oocyte, still arrested at diplotene stage undergoes a 
growth phase, which consists of a period of hypertrophy due to massive synthesis of 
cytoplasmic components. The storage of organelles and macromolecules that will be 
inherited by the embryo requires the chromosomes to decondense and the chromatin 
to become transcriptionally active; indeed, in the nucleus intense RNA synthesis is 
detectable until it stops at the end of the growth phase, which is species-dependent 
[58]. For example, in the early antral follicle mouse oocytes growth is already complete 
[59], while bovine oocytes are still growing [60].  
 The systemic LH surge determines the selection of just one large antral follicle 
(or more in polyovulatory species) that continues growing until reaching ovulation, 
while the other follicles will be eliminated through atresia. Only at this time, the 
oocyte(s) within the selected pre-ovulatory follicle(s) is able to resume meiosis and 
mature. What is generally called ‘oocyte maturation’ ends when the oocyte complete 
meiosis I and part of the DNA is extruded with the first polar body, and the oocyte’s 
chromosomes arrange in the metaphase II plate (MII stage). After first PB emission, 
the majority of the cytoplasm is retained in the oocyte [61]. Meanwhile, the granulosa 
cells are responsible for the process of cumulus expansion, producing a muco-elastic 
extracellular matrix, leading the COC to detach from the follicle wall [62]. Then the 
follicle wall breaks and ovulation takes place: the expanded COC is extruded from the 
ovary and moves to the oviduct where fertilization will take place. The meiosis process 
will complete after fertilization and extrusion of the second polar body. The remaining 
peripheral granulosa cells and the theca cells form the corpus luteum responsible for 
the production of high levels of progesterone required for successful implantation of 
the embryo and maintenance of the pregnancy [49] (Figure 2.1). 
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Figure 2.1 Schematic representation of oocyte and follicle maturation stages from fetal 
life to fertilization. From [37]. 
 
 
 It is clear that folliculogenesis and oogenesis are two strictly interconnected 
events and their correct coordination determines the quality and competence of the 
female gamete [56, 57]. Follicles, and especially granulosa cells, are an essential niche 
for growing oocyte survival, nourishment and regulation [37]. 
 The communication between these two compartments is bidirectional and it is 
mediated by a complex junctional communication system and several paracrine factors 
(reviewed in [61]).  
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 Prominent extensions, called transzonal projections (TZP), on the surface of 
granulosa cells terminate on the oocyte plasma membrane interacting through gap 
junctions and adherens junctions. TZPs may be formed by F-actin (A-TZP) or 
microtubule –rich structures (M-TZP) and allow the transport of ions, metabolites, 
regulatory molecules. Even transport of RNA transcripts through micro-vesicles has 
been recently proposed [61, 63]. As the oocyte volume increases, TZP complexity 
evolves to assure correct support to the gamete [61]. Gap junctional mediated 
communication system is proved to be essential for correct oocyte maturation and 
developmental competence in cattle [64], as well as in other mammals [65, 66]. 
 Paracrine factors are mainly oocyte-secreted factors (OSF) including members 
of the transforming growth factor- family, such as bone morphogenetic protein 15 
(BMP15) and growth differentiation factor 9 (GDF9), and fibroblast growth factors 
(FGF) (reviewed in [67]). OSF alone are needed for cumulus expansion in mice [68], 
while in cattle, pig and rat is suggested that OSF alone are less influential than in the 
mouse [69]; indeed, the interaction between OSF and cumulus cells derived factors, 
such as FGF2 and kit ligand (KL), is essential for COC maturation [70, 71].  
 Moreover, both paracrine factors and ZTP are important to control meiosis. In 
fact, they regulate signaling of natriuretic peptide precursor C (NPPC), secreted by 
granulosa cells, which is responsible for maintaining meiotic arrest in mutant mice and 
in bovine oocytes in vitro [72, 73]. NPCC stimulates cGMP production, which is 
transferred to the oocyte through gap junctions and keeps cAMP levels required to 
prevent the synthesis of maturation promoting factor (MPF).  NPPC production is 
inhibited by LH and cGMP flow to the oocyte is decreased after reduced gap junctions’ 
functionality, thus promoting meiosis resumption [74]. Interestingly, NPPC is also 
regulated by intrafollicular steroids, including estradiol and progesterone. In cattle, 
steroids enhance NPCC action slowing nuclear maturation and increasing gap 
junctions mediated cumulus-oocyte communication in bovine COC. Their combination 
in pre-IVM culture also enhanced embryo quality [75, 76]. 
 
 
2.1 Cell division during folliculogenesis 
 
 During folliculogenesis cell proliferation and cell division are two fundamental 
processes; indeed, folliculogenesis involves a huge rate of cell proliferation making 
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granulosa cells mitosis a fundamental event in the follicle. On the other hand, oocyte 
meiosis prepares a haploid gamete ready for fertilization and production of a viable 
embryo. Mitosis is the process leading to faithful replication of somatic cellular 
contents, including DNA, and the production of two daughter cells with identical genetic 
and cellular composition. By contrast, meiosis is exclusive of germ cells and ultimately 
results in the production of gametes with half the DNA content so that, after fertilization, 
the zygote will contain the full complement of genetic material from the female and the 
male counterparts [56, 77]. 
 Mitosis is “cyclical” in nature since the two daughter cells are diploid (2n) and 
ready to start forthcoming cycles of DNA replication and cell division, while meiosis is 
more unidirectional as the two gametes need to undergo fertilization to achieve the 
diploid status and be able to proliferate through mitosis for embryogenesis [77]. Even 
if they are two different types of cell division they share some common features, 
especially during the last phase of division, and their correct completion is important to 
avoid mistakes leading to cell defects and/or cell death. 
 
 
2.1.1 Oocyte maturation  
 
 After LH surge, a mammalian oocyte that has terminated the growth phase and 
is arrested at prophase I, initiates the so-called meiotic maturation that encompasses 
the period in which the oocyte progresses from the prophase I stage to the Metaphase 
of the second meiotic division (MII stage), when meiotic progression stops again until 
fertilization occurs. As such, oocyte maturation involves both a nuclear and a 
cytoplasmic maturation. Cytoplasmic maturation involves cytoplasmic changes 
required to prepare the cell for fertilization and embryo development. The oocyte’s 
cytoplasm contains a variety of organelles typical of most cells such as mitochondria, 
Golgi apparatus and endoplasmic reticulum, but also some oocyte-specific organelles 
as, cortical granules, annulate lamellae, acidic granules. During maturation only some 
organelles undergo transformation (cytoskeletal elements, cortical granules and 
endoplasmic reticulum) while others remain stable. Cytoplasmic maturation remains 
poorly understood but has been shown to be fundamental for the completion of 
meiosis, the prevention of polyspermy and early embryonic development [51, 61]. 
		 14	
 Nuclear maturation consists in chromosome segregation and formation of the 
metaphase plate of the second meiotic division leading to the MII stage oocyte. Before 
meiotic resumption the oocyte contains a large nucleus, called Germinal Vesicle (GV), 
in which chromosomes are decondensed and transcriptionally active during the oocyte 
growth phase. Transcription is globally silenced toward the end of the oocyte growth 
phase and transcription is in fact already silenced when the chromosomes condense 
and the GV breaks down (GVBD). 
 At GVBD the meiotic spindle starts to assembly; the microtubule spindle 
assembles around the paired homologous chromosomes. This spindle segregates half 
of the homologous chromosomes in a small cell, that is the first polar body through an 
asymmetric division. The remaining chromosomes are captured by a second meiotic 
spindle and the oocyte arrests at this stage until fertilization. Only after fertilization the 
oocyte eventually resume and complete meiosis II undergoing a rapid anaphase II and 
telophase II with the elimination of another half of the genetic material in the second 
polar body, The chromatids remaining in the oocyte decondense and form a 
pronucleus that will fuse with the male pronucleus, giving birth to the zygote which will 
start dividing by mitosis to form the blastocyst [47, 77-79] (Figure 2.2). 
 
 
 
 
Figure 2.2 Schematic representation of the two meiotic divisions leading to an oocyte 
ready to be fertilized and progress into an embryo. From [79]. 
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2.1.2 Mitotic cellular division  
 
 The cell cycle of somatic cells is characterized by two phases: interphase and 
mitotic phase (M-Phase). Interphase includes an initial growth phase (called Gap1 
phase, G1) and a DNA synthesis phase (S), during which the genomic DNA is 
replicated, followed by a G2 phase, in which the cell ultimate preparatory events that 
would later allow the cell to produce daughter cells with enough organelles and 
properly replicated genetic material. The M-phase is generally divided into four stages: 
prophase, metaphase, anaphase, telophase and the last cytokinesis stage giving birth 
to the two daughter cells. During prophase, loose replicated chromatin condenses in 
individual chromosomes and the nuclear envelope starts to fragment. Chromosomes 
align along the mitotic plate during metaphase and microtubules attach to the 
duplicated centrosomes. This phase is the most important and needs to be strictly 
spatiotemporally regulated to assure the proper chromosomal positioning and number 
before segregation. During anaphase, the two centrosomes reposition to the opposite 
spindle poles thanks to motor proteins and sister chromatids segregate. Finally, during 
telophase each of the new complete DNA genomic set is surrounded by a newly 
formed nuclear envelope. Cytokinesis, leads to the division of the cytoplasmic 
compartment and actually starts at ana-teplophase, being highly coordinated with 
caryokinesis (i.e. segregation of the genetic material in two nuclei). Cytokinesis is 
ultimately responsible for the division of the two daughter cells through the formation 
of an initial cleavage furrow by an actin-myosin contractile ring, which halts when it 
encounters the midbody. During final abscission, the opposing bridge membranes fuse 
and the two cells finally divide [80] (Figure 2.3). 
 
 
 
Figure 2.3 From [80]. Schematic representation of mitotic division stages.  
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2.1.3 The mitotic and meiotic spindles 
 Even if there is a great difference between mitotic and meiotic division, in both 
types of cellular division faithful chromosome segregation and completion of division 
in the last stages through cytokinesis and the extrusion of the polar body, respectively, 
are essential to achieve healthy new daughter cells. To this aim spindle made up of 
microtubules is the major structure playing an important role in both systems, even if 
with some differences, to orchestrate and spatiotemporally drive chromosomes 
movement during last stages of cell division and in the physical separation of the cells 
through the formation of the actin-myosin contractile ring [81].   
 In mitosis, the structure of the spindle at each mitotic phase has been well 
described. At anaphase two microtubule populations form the spindle: astral 
microtubules that radiate from the centrosomes toward the cell cortex and the midzone 
microtubules that form an antiparallel array between the separating chromosomes. The 
microtubule attachment site of chromosomes are the kinetochores, which enable the 
two sister chromatids of a chromosome to be attached to opposing spindle poles and 
to be pulled to opposite sides during cell division. This anaphase spindle determines 
the position at which the contractile ring, and subsequently the cytokinetic furrow forms. 
The cleavage furrow together with the central spindle microtubules forms the midbody 
that controls the correct cell division. The division plane usually bisects the anaphase 
spindle and, consequently, the cell. [81, 82] (Figure 2.4).  
 In the oocyte, the meiotic spindle lacks the centrosomes and the astral 
microtubules, while spindle midzone microtubules induce contractile ring constriction 
but do not define the site of polar body extrusion (the division site in the oocyte), which 
instead is a singular location on the cortex where the spindle is anchored and is 
determined by chromatin itself and not by the microtubules. In the mouse, it has been 
shown that the meiosis I spindle forms approximately at the center of the oocytes and 
then moves eccentrically toward the oocytes periphery. I other mammals such as cows, 
the GV is already found eccentrically in the fully-grown oocytes, thus the spindle 
migration toward the oocytes periphery is less probable in this species. Nevertheless, 
at the oocyte periphery the meiotic spindle is found perpendicularly oriented to the 
adjacent cortex. Its migration and rotation depend on microtubule/actin filament 
cytoskeleton. The meiosis II spindle then forms already off center [81] (Figure 2.5).  
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Figure 2.4 Adapted from [82]. Microtubules (red) in dividing Hela cells (A) and 
representation of microtubule spindle during anaphase and telophase of somatic cells 
(B).  
 
 
 
Figure 2.5 Representation of tubulin meiotic spindle (green) during maturation of a 
mammalian oocyte [61]. 
 
 The spindle functioning is orchestrated and strictly controlled by several 
molecules. The best characterized of these controllers during mitosis is the 
chromosomal passenger complex (CPC). The CPC is part of the bigger spindle 
assembly checkpoint (SAC) and is composed by Aurora kinase B (AURKB), the inner 
centromere protein (INCENP) and the chromatin-targeting subunits Survivin and 
Borealin. This complex is dynamic throughout the mitotic division and it localizes from 
the centromeric region of the chromosome to the midzone during the last phases of 
mitosis [83, 84]. AURKB acts as an error-correction machinery allowing for 
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kinetochore-microtubule interactions to create and destroy, phosphorylating 
microtubule-interacting proteins, until the chromosomes are correctly oriented and 
stabilized. The other three members of CPC control its targeting, enzymatic activity 
and stability. The SAC complex acts as a messenger for CPC information for the onset 
or the delay in chromosome segregation at anaphase thus assuring the correct timing 
for division [85]. The CPC complex is described to be conserved also in meiotic spindle 
[86, 87], but with some differences in its dynamical localization. Indeed, in meiosis I it 
does not transfer to central spindle microtubules but remains at the centromeres of the 
segregating bivalents until late anaphase I to preserve centromere cohesion, while it 
starts to accumulate at the spindle midzone, as in mitosis, during metaphase II-
anaphase II transition [88, 89]. Importantly, in mouse AURKC regulates oocyte 
meiosis, while in bovine this function is exerted by AURKB [90]. 
 
 The major consequence of missegregation of chromosomes occuring during 
cell division is aneuploidy, i.e an abnormal number of chromosomes in the daughter 
cells [91]. Missegregation during meiosis causes aneuploidy in progeny or fertilized 
eggs, leading to infertility, miscarriages and birth defects [79, 92]. Errors during meiosis 
are caused by age-related changes to structure responsible for chromosome 
attachment to tubulin; one hypothesis is cohesin complex deterioration which is evident 
in mouse studies, but still to be proven in human [93, 94]. There are also age-
independent pathways causing errors during meiosis such as defects in homologous 
recombination, insensitivity to meiotic checkpoint activation or instability of the meiotic 
spindle [79]. While during mitosis, aneuploidy is considered the consequence of failure 
in CPC and SAC checkpoints signaling [84] and it is a feature of tumoral cells, hence 
might facilitate tumorigenesis [95, 96].  
 
 
 
2.2 In vitro maturation (IVM) value as commercial tool and experimental model   
 
 Oocyte maturation, intended from meiotic resumption and progression to the 
mature stage (MII), can be achieved in vitro. The fundamental difference between in 
vitro and in vivo oocyte maturation lies in the fact that in the follicle oocytes are 
maintained under meiotic arrest and the maturation of selected oocytes can start only 
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after hormonal stimulation (LH-dependent). While in vitro, fully-grown oocytes isolated 
from mid-large antral follicles and placed under suitable culture environment undergo 
spontaneous (LH-independent) meiotic resumption and progress to MII phase with 
polar body I extrusion [97]. In vitro, oocytes resume meiotic resumption generally 
earlier when compared to the in vivo counterpart. Thus, generating an asynchrony 
between oocyte nuclear and cytoplasmic maturation, which is generally considered 
one of the drawback of IVM [98].   
 Nevertheless, in vitro maturation (IVM) was first established in rodents [99] and 
then progressively extended to many other species such as pig, sheep, goat, horse 
and cow being used for both scientific and commercial interests [100].  
 In particular, IVM of bovine oocytes is being greatly exploited by bovine industry 
and in research field since cow oocytes mature in vitro with a very high efficiency (over 
90%). Indeed, in the last century IVM and consequent in vitro fertilization (IVF) to 
achieve in vitro embryo production represents a significantly growing field [101]. 
Assisted Reproductive Technologies (ARTs) are extensively used in bovine industry 
for high quality embryo production and to quickly propagate genetics, thanks to the 
continuous improvement of culture media [101]. 
 On the other hand, for research purposes IVM represents a good accessible 
investigation strategy to easily observe the process of maturation. Scientists could also 
test the action of hormones, growth factors and other biologically active molecules in 
this simplified system, rapidly and without confounding influence of in vivo elements 
such as the follicle, the ovary and the organism [102]. 
 Finally, being a monovular species, bovine is a suitable model to study woman 
reproduction and to ameliorate ARTs that are extensively used in human medicine and 
IVM has been introduced as an alternative to minimize or eliminate the risks and 
disadvantages associated with intense gonadotropin stimulation of the ovary [100]. 
 
 
2.3 Mammalian folliculogenesis and oogenesis regulation 
 
 Folliculogenesis and oocyte growth and maturation toward developmental 
competence acquisition are gradual processes strictly regulated by checkpoints to 
assure the correct timing for every stage. Every checkpoint is controlled by numerous 
molecules and hormones, which are shortly listed here (reviewed in [30]).  
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2.3.1 Molecular regulation 
 
 Until puberty, follicle activation is repressed by several factors such as 
spermatogenesis and oogenesis specific basic helix-loop-helix 2 (Sohlh2) [103],	anti 
mullerian hormone (AMH) [104] and Phosphatase and tensin homolog (Pten) [105]. In 
mice, the transition from primordial to primary follicle is mainly driven by the oocyte, 
that is characterized by upregulated expression of members of the transforming growth 
factor (TGF)-β superfamily, including Bone morphogenetic proteins (Bmp5, Bmp6, 
Bmp15), Growth differentiation factor 9 (Gdf9), Transforming growth factors (Tgfb2, 
Tgfb3), as well as other growth factors such as Basic fibroblast growth factor (bFgf) 
and Leukemia inhibitory factor (Lif) regulated by several master transcription factors 
(reviewed by [106]).  
 These events occur also in other species and, for example, it is postulated that 
changes in the oocyte transcriptome in cattle happens during the following passage 
from primary to secondary follicle, which takes longer than in mouse, and is 
characterized by nucleolus reorganization and activation determining the beginning of 
RNA synthesis [107]. Moreover, at this point bidirectional communication between 
oocyte and granulosa cells through gap junctions initiates and the regulatory loop 
regulating signaling and metabolic pathways between the two compartments is 
probably mainly driven by Gdf9 and Bmp15, which have key roles especially in 
glycolysis and cholesterol biosynthesis of cumulus cells [108]. 
 In cattle Follicle stimulating hormone receptor (FSHR) mRNA expression and a 
progressive responsiveness to gonadotropins is observed during the secondary follicle 
stage [109-111]. The transition to tertiary follicle is characterized by intensive mRNA 
and rRNA transcription. Locally produced factors, such as insulin-like growth factor-I 
(IGF-I) and members of the TGF-β superfamily, still play an important role in bovine 
preantral follicle development [106]. 
 In cattle, the development of the antral follicle is completely dependent on 
gonadotropins; indeed, the growing follicles express transcripts encoding 
steroidogenic enzymes, gonadotropin receptors and local regulatory factors together 
with their receptors, meanwhile the oocyte transcriptome becomes quiescent and the 
nucleolus inactivate [107]. During the last stages of follicular growth, the follicle 
responds to increasing LH levels, the resumption of meiosis in the oocyte is likely 
promoted by epidermal growth factor (EGF)-like factors Amphiregulin (Areg), 
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Epiregulin (Ereg) and Betacellulin (Btc) released by granulosa cells, since the oocyte 
does not express LH receptors. In addition, meiotic resumption requires activation of 
maturation-promoting factor (MPF) resulting in the germinal vesicle breakdown 
(reviewed in [112]). 
 The subsequent stages of meiotic maturation are regulated by the Anaphase 
Promoting Complex (APC) and other key factors previously described. The arrest at 
metaphase II is under the control of cytostatic factor (CSF). All these regulatory 
complexes are in turn regulated by kinases, phosphates, polyadenilation [113]. Finally, 
after cumulus expansion, the LH surge determines follicle rupture and ovulation. Also 
these events are strictly coordinated by different extracellular signal-regulated kinase 
(ERK1/2) target genes, as shown in vivo in ERK1/2 depleted mice; for example, 
cytochrome P450 Cyp19a1 and Sulfotransferase Family 1E Member 1 (Sult1e1), 
which regulate oestradiol biosynthesis and activity, Steroidogenic Acute Regulatory 
Protein (Star) and cytochrome P450 Cyp11a1, which are associated with granulosa 
cell luteinisation, the EGF-like factors Areg, Ereg and Btc and the cumulus expansion 
factors Prostaglandin-endoperoxide synthase (Ptgs2), TNF Alpha Induced Protein 6 
(Tnfaip6), Hyaluronan Synthase 2 (Has2), Pentraxin-related protein (Ptx3) [114]. 
 
 
2.3.2 Hormonal regulation and progesterone (P4) role in the follicle development 
 
 The main hormones involved in folliculogenesis are Gonadotropin-releasing 
hormone (GnRH), secreted by the hypothalamus, which stimulates the release of 
Follicle-Stimulating Hormone (FSH) and LH from the anterior pituitary gland. FSH is 
responsible for follicle development, promoting antral follicles growth and 
differentiation of somatic cells, ensuring they acquire sensitivity to LH. LH is then 
responsible for triggering ovulation and oocyte maturation.  
  Estrogen and progesterone (P4) also play key roles. Estrogen is a steroid 
hormone produced by the granulosa cells of the developing follicle exerting a negative 
feedback on LH production until the oocytes is ready for ovulation, it then leads to the 
LH surge. P4 is a steroid hormone synthesized by the ovary at different levels 
depending on gonadotropin stimulation and the physiological status of the ovary [115, 
116]. During the oestrus cycle of cattle, P4 circulating levels regulate pulsatile secretion 
frequency of gonadotrophin-releasing hormone (GnRH), which in turn regulates LH 
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pulse frequency. The ovulation of a dominant follicle is driven by LH pulse frequency: 
high P4 concentrations determine low LH pulse frequency and the dominant follicle 
undergoes atresia; on the contrary, low P4 concentration after luteolysis leads to 
ovulation of the dominant follicle after production of oestradiol and inhibin [117, 118].  
 The P4 well known effects on reproductive function include also the formation 
and maintenance of the corpus luteum [116], the effects on reproductive tissues, 
especially the uterus and mammary gland [119] to prepare them for the pregnancy, 
and the placenta formation [120, 121]. It is also involved in regulating the mating 
behavior [122]. It is demonstrated that it has a role also during rodents ovulation since 
blocking P4 leads to anovulation [123-125] and more recent studies using P4 receptor 
knockout mice demonstrate that this action is mediated, at least in part, through the 
nuclear Progesterone Receptor (PGR-A and PGR-B) [126, 127].  
 
 
2.3.3 Insights into P4 and P4 receptors’ role in folliculogenesis 
 
 The role of P4 before ovulation is still poorly understood even if some indications 
suggest its contribution during folliculogenesis and oocyte maturation. Indeed, P4 
levels in the follicular fluid of preovulatory follicles between LH surge and ovulation are 
very high [128]. Moreover, cumulus cells exhibit receptors for P4 and secrete P4 during 
oocyte maturation suggesting a role in oocyte competence. It has been demonstrated 
that inhibiting P4 production in vitro leads to reduced embryo development in cattle 
[129]. Additionally, in vivo studies showed elevated P4 during development of the 
ovulatory follicle is associated with improved pregnancy rates in lactating dairy cattle 
[130].  
 There is evidence that P4 potential actions are exerted both on follicular cells 
and on the oocyte. In the follicular compartment, periovulatory P4 surge is responsible 
for the inhibition of follicular growth, in particular in vivo studies showed that it 
decreases the rate of granulosa cells mitosis [131] during the oestrus cycle and 
pregnancy of different species including hamster [132, 133], rabbit [134], rats [135], 
mice [136] and also in primates [137]. Strikingly, this role appears independent of its 
ability to influence gonadotropin levels, so it is likely that it acts directly on granulosa 
cells. This hypothesis is further confirmed by in vitro studies on granulosa cell cultures 
[138-142]. While in luteal cells after ovulation, P4 promotes its own synthesis and 
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prevents apoptosis to maintain luteal cells. This happens also in rat luteal cells, which 
do not express PGR receptors. This further suggests some signaling pathway other 
than the classical genomic one.  
 The role of progesterone in inducing oocyte maturation in frog and fish oocytes 
is well known [143-146], while in mammalian oocyte its role is still debated. Despite in 
rodents there is little evidence of a role in oocyte maturation [147], in other species 
there is growing evidence of its contribution. In in vitro culture of bovine and porcine 
oocyte and its surrounding cumulus cells, inhibiting P4 synthesis or blocking PGR 
receptor, which is not expressed in the mouse counterpart, impairs cumulus expansion 
[129, 148, 149]. Moreover, recent studies have shown that oocyte meiotic and 
developmental competence are affected by P4 as well as by both classic and non-
genomic receptors [129, 150, 151]. 
 
 Besides the classical nuclear Progesterone Receptor (A and B) [152], which 
mediates P4 signaling regulating genes cascade, over the last years other putative 
non-genomic P4 receptors have been investigated. The presence of non-genomic P4 
receptors could justify some rapid responses to P4, not compatible with genomic 
signaling transduction, which is slow and complex. Moreover, studies in PGR-A/PGR-
B null mice showed a normal follicular growth and, since granulosa cells of immature 
follicles respond to P4, these newly proposed receptors could be mediating P4 actions 
before gonadotropin surge [153, 154]. Finally, luteal cells of short luteal phase species, 
as mice and rats, do not express PGR and, therefore, P4 luteotropic action may be 
transduced by other receptors [155, 156].   
 
 The putative non-genomic, membrane-bound P4 receptors are found to be 
expressed also in mammalian ovaries and include: 
 - A family of three Membrane Progestin Receptors (MPR) (isoforms mPRα, mPRβ and 
mPRγ). Based on amino acid sequence homology, the mPRs belong to a larger family 
of 11 highly conserved mammalian paralogs termed the PAQR (progestin and adipoQ 
receptors). They were first identified in fish oocytes [157, 158] and then also being 
expressed in rat ovary [159] and in bovine [129] and porcine oocytes [160]. 
- Progesterone Receptor Membrane Components (PGRMC1 and PGRMC2) 
expressed in both follicular cells and oocyte of different species indicating a possible 
role in mediating P4 action in this system (see PGRMC1 overview chapter). Importanly, 
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it must be underlined that both PGRMC1 and PGRMC2 also exert P4 independent 
function in mammalian cells [161]. 
 
 From this premise, it is clear that many factors and molecules are involved in 
reproductive function and the complex folliculogenesis regulation is continuously under 
investigation. Nonetheless, several mechanisms of action and molecules are still 
poorly understood or unknown. Hence in this study we focused on Progesterone 
Receptor Membrane Component 1 (PGRMC1) as a putative key factor involved in 
oocyte competence acquisition and oocyte maturation having a role in regulating 
folliculogenesis at different stages in both the somatic and germinal cells. 
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3. PGRMC1 overview 
 
 
3.1 Cloning and nomenclature 
 
 Progesterone Receptor Membrane Component 1 (PGRMC1) is a small heme-
binding protein, which is expressed and conserved in several animal tissues and 
characterized by a wide variety of biological functions [161]. PGRMC1 protein was first 
discovered and described in 1996 by two independent groups. Selmin et al. cloned 
PGRMC1 cDNA as a gene product responsible for reducing dioxin toxicity in rats; the 
25 kDa dioxin-upregulated protein was named 25-Dx [162]. While Meyer group purified 
this protein from swine liver membrane as a component of a membrane associated 
P4-binding activity and therefore named it membrane progesterone receptor (mPR) 
[163]. In 1998, the same group cloned by homology to its porcine counterpart the 
human PGRMC1 gene, on chromosome X, which they firstly called Heme 
Progesterone Receptor 6 (Hpr6) [164].  
 Since then PGRMC1 has been found and reported in different areas of 
biological research in mammalian tissues (see 3.4 paragraph) under different 
synonyms, until it was officially and univocally referred to as Progesterone Receptor 
Membrane Component 1 (PGRMC1), approved by HUGO Gene Nomenclature 
Committee (HUGO Gene Nomenclature Committee ID HGNC:16090). 
 
 
3.2 Lower eukaryotic homologues 
 
 PGRMC1-like proteins have been described also in non-mammalian species.  
In 2003, Craven group cloned a Saccharomyces cerevisiae yeast member of the 
MAPR gene family and the encoded protein was called Damage Response Protein 
Related to Membrane Associated Progesterone Receptors (DAP1). DAP1 shows 
similarity to PGRMC1 [165] and in yeast it mediates resistance to azole antimycotics 
[165], regulates cytochrome P450 proteins [166] and mediates iron homeostasis [167]. 
 In 2004 Runko et al. published the discovery of C.elegans protein VEM-1 as the 
homologue of PGRMC1 they found in rat neurons [168], sharing 37% amino acid 
identity. This protein is involved in neuron guidance and axon formation in a variety of 
neurons in the nematode ventral midline [168]. 
		 26	
 Moreover, Song et al. [169] described an ortholog called AT2G24940 in 
Arabidopsis which NMR structure revealed a cytochrome b5 domain highly 
homologous and conserved between this and the mammalian PGRMC1 protein [170, 
171]. Nonetheless, little is known about its functions in plants since no functional 
studies are available.  
 
 
3.3 PGRMC1 structure  
 
 PGRMC1 is a 194-aminoacid long protein and has a predicted molecular weight 
of 21 KDa in most mammalian species. According to electrophoretic mobility the 
molecular weight is of 25-28 kDa. Frequently, electrophoretic analysis followed by 
Western blotting detects a second band of double molecular weight. This band was 
thought to be a disulfide link dimer, since it disappeared after treatment with reducing 
agents [172]. However, in other studies treatments with reducing agents failed to 
disrupt this putative dimeric form and described this as a not membrane-bound 
PGRMC1 with high molecular weight, since it did not disappear when detergents were 
omitted from the extraction buffer. On the contrary, the 25Kd resulted the membrane 
bound form [173].  
 The existence of a PGRMC1 dimer is further confirmed by recent studies by 
Kabe et al. that showed that PGRMC1 dimer formation is heme-dependent [174]. 
Moreover, additional bands of >50 and < 50 kDa molecular weight are frequently 
detected in western blots at long exposures (depending on cell types) and PGRMC1 
siRNA treatment depletes these higher forms as well as the lower band, confirming 
that PGRMC1 exits in multiple molecular weight forms [175]. 
 PGRMC1 is a member of the Membrane Associated Progesterone Receptor 
(MAPR) family, which is a sub-family of proteins sharing a basic cytochrome b5 (Cytb5) 
domain fold [176]. In mammals, MAPR has four family members: PGRMC1 (the 
archetypal member of the family), PGRMC2 (strictly related to the previous one), 
Neudesin and Neuferricin [176].  
 Human PGRMC1 is composed of 194 aminoacids in a single chain, is predicted 
to be anchored to the cell membrane through a N-terminal transmembrane domain and 
has a putative cytoplasmic C-terminal Cytb5-like domain based on sequence analysis 
[177, 178] (Figure 3.1).   
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Figure 3.1 Graphical representation of PGRMC1 structure. In particular its proposed 
localization to the membrane of cellular organelles, potentially binding small 
hydrophobic ligands. From [179] 
 
 
Kabe et al. recently published the NMR and crystal structure of PGRMC1 and they 
showed for the first time that after binding to heme PGRMC1 forms a stable dimer that 
is required for binding and activation of CyP450 enzymes and epidermal growth factor 
receptor (EGFR). The dimer is dissociated into monomers by Carbon Monoxide (CO) 
that interferes with the heme-stacking interface [174] (Figure 3.2).  
 
 
 
 
Figure 3.2 Model of PGRMC1 structural regulation from monomer to dimer in response 
to haem and CO. From [174]. 
 
 
 This study also confirmed some of the previous predictions made on PGRMC1 
structure, such as the presence of different peptide sequences that might be involved 
in its interaction with other cellular proteins or molecules for signal transduction. In 
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particular, the consensus motifs Src homology 3 (SH3) target sequence at P63 and 
the Src homology 2 (SH2) target sequences centered at Y139 and Y180. They are 
adjacent to one another and lie on the opposite surface of the heme-binding site. 
Tyrosine phosphorilation of SH2 Y139 and Y180 could be necessary to recruit proteins 
to PGRMC1 surface and, on the other hand, SH3 and SH2 on Y181 are probably 
negatively regulated by constitutive phosphorylation of adjacent Casein Kinase 2 
(CK2) consensus motifs at S57 and S181 [174]. Therefore, this further suggests that 
phosphorylation status seems to have an important role in orchestrating PGRMC1 
function as Cahill stated after describing that in vivo PGRMC1 is differentially 
phosphorylated [180, 181] (Figure 3.3). 
 
 
 
 
Figure 3.3 PGRMC1 heme dimer structure highlighting important peptide sequences 
possibly involved in its interaction with different proteins and molecules.  From [180]. 
 
 
 Moreover, in silico analysis shows that PGRMC1 presents also 3 sumoylation 
sites at lysine residues 136, 187, and 193 (http://sumosp.biocuckoo.org/online.php) 
[182]. Sumoylation, which involves the rapid and reversible covalent binding of small 
ubiquitin-like modifier (SUMO) proteins, is another process that is involved in regulating 
PGRMC1 function [173]. 
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3.4 PGRMC1 localization in mammalian tissues 
 
 From its first description in rat and swine liver [162, 163] PGRMC1 has been 
found to be expressed in a very wide variety of mammalian organs and tissues, and in 
several tumors as well (see chapter 8). 
It was described in the rat adrenal cortex [183], in rat nervous system [184-188] and in 
several reproductive organs.  
 In particular, PGRMC1 is expressed in rat and human uterus and placenta [189], 
in macaque endometrium [190], in bovine [151, 191-193] and canine reproductive 
systems [194]. Specifically, PGRMC1 has been described also in the ovary [151, 191, 
195]. In the ovarian follicle it is found in the somatic compartment, where it is 
expressed in granulosa and luteal cells of rodent, bovine and canine ovaries [129, 191, 
194, 196-198], and also in bovine and rat oocyte [150, 151, 195]. 
 From a subcellular point of view, PGRMC1 is expressed in many cellular 
compartments. Indeed, PGRMC1 has a transmembrane domain so it is a membrane 
bound protein found in several membranous compartments: the nuclear and plasma 
membranes [189, 195, 199], the endoplasmic reticulum [163, 183, 188], the Golgi 
apparatus [188], the endosomes [200] and the secretory vesicles [201]. Interestingly, 
it localizes also to the mitotic spindle, interacting with microtubules [202-204], and then 
it associates to the midzone and the midbody during cell division [204]. Similarly, in 
meiotic spindle PGRMC1 associates to condensing chromosomes and then to 
centromeric region of metaphasic chromosomes during metaphase I and metaphase 
II, while during ana/telophase I it concentrates between separating chromosomes [150, 
151]. 
 This protein was also described within the nuclear compartment [173, 175, 189, 
205-207] in which it localizes also to the nucleoli both in somatic cells [208-210] and in 
nucleolar precursor bodies of the zygote [151] (Figure 3.4). 
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Figure 3.4 Image showing the plethora of PGRMC1 subcellular localizations. Data 
from: [151, 163, 173, 175, 183, 188, 195, 199-208, 211-220].  
 
 
 It is clear from the disparate multiplicity of PGRMC1 localizations that its 
function(s) may vary according to the organ/tissue considered. Moreover, its high 
subcellular compartmentalization suggests that at each site PGRMC1 might participate 
in the control of precise and diverse cellular processes, depending on the protein(s) 
with which it interacts at each sub-cellular site. In fact, this is reflected by a very wide 
range of proposed functions for PGRMC1, the majority of those is currently under 
investigation. Our main hypothesis is that in every specific subcellular localization 
PGRMC1 interacts with different proteins and, consequently, it is involved in diverse 
pathways resulting in distinctive functions. 
 
 
3.5 Putative PGRMC1 ligands and functions 
 
 Although PGRMC1 is a member of MAPR protein family, it has no homology 
with the nuclear or membrane-associated steroid receptors [176] but it is more similar 
to Cyt b5 heme binding proteins, sharing key structural motifs. Indeed, the best known 
PGRMC1 biochemical function is binding to heme and, consequently, binding and 
activating a wide range of cytochrome P450 proteins; thus, regulating in an heme-
dependent manner drugs, hormones and lipids metabolism [161, 178]. 
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 For example, PGRMC1 regulates cholesterol synthesis interacting with 
CYP51/lanosterol demethylase [221], which catalyzes the essential reaction from 
lanosterol to cholesterol in the sterol synthetic pathway. Moreover, PGRMC1 interacts 
with INSIG1(insulin-induced gene)/SCAP (SREBP cleavage activating protein) 
/SREBP (sterol regulatory element binding protein) complex that regulates sterol 
precursors synthesis, but its role in modulating this complex is still unknown [222]. It 
also binds several drug metabolizing P450s, including CYP2C2, CYP2C8 [223] and 
CYP3A4, a major enzyme responsible for the metabolism and clearance of almost 50% 
of all known drugs, CYP7A1, an important enzyme involved in bile acid synthesis and 
CYP21A2, a progesterone 21-hydroxylase required for production of glucocorticoids 
and mineralocorticoids [221]. 
 PGRMC1 is also involved in embryogenesis; in fact, both mammalian PGRMC1 
and its nematode homologue VEM-1 regulates the fidelity of nerve cord axonal 
guidance along the ventral midline of nematodes and the spinal cord of rats [168, 184, 
185]. What’s more, this function relies on the vesicle trafficking properties of PGRMC1 
to expose specific cell surface receptors required during axonal guidance, indicating 
another possible function of this protein [161].  
 Moreover, for its localization to the outer mitochondrial membrane, PGRMC1 
interacts with Ferrochelatase (FECH), the final enzyme in the heme synthetic pathway 
[224].  
 PGRMC1 effect on cell proliferation and division is another attested PGRMC1 
function as suggested by its localization to the meiotic and mitotic spindle in both 
somatic cells and oocytes and its co-localization with AURKB in oocytes [150, 204]. 
Studies conducted in bovine oocytes (which represent the base knowledge for the 
present PhD research) demonstrated that injecting an antibody against PGRMC1 into 
immature oocytes arrested the majority of the oocytes at prometaphase I during bovine 
oocyte meiosis and prevented completion of meiosis I [151]. Moreover, several studies 
inhibiting PGRMC1 function with different techniques impaired cell proliferation in rat 
granulosa cells, ovarian, breast and lung cancer cell lines. The same results were 
observed injecting PGRMC1 depleted-SKOV3 human cancer cell lines into athymic 
nude mice, where these cells failed to proliferate and form tumors when compared to 
the wild type counterpart. [204, 207, 211, 225]. Moreover, studies have shown that in 
spontaneously immortalized granulosa cells (SIGCs) and ovarian cancer cells SKOV-
3, PGRMC1 interacts with β tubulin microtubules as assessed by in situ proximity 
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ligation assay. The stability of the microtubules could be regulated by P4-PGRMC1 
interaction consequently affecting the rate of mitosis; the presence of P4 causes slow 
cell proliferation and delayed mitotic progression [204].  
 Finally, there is strong evidence of PGRCM1 role in cancer biology. Indeed, 
PGRMC1 is overexpressed in a wide range of tumors, compared to corresponding 
normal tissues, in which it promotes tumor growth and chemoresistance. Kabe and 
colleagues recently described PGRMC1 heme-dependent dimer formation as essential 
for interaction of this protein with cytochrome P450 proteins but also with EGFR, 
respectively enhancing chemoresistance and proliferation of cancer cells [174]. 
 
 
3.6 Last but not least - Is PGRMC1 a Progesterone Receptor? 
 
 PGRMC1 was initially cloned in search of membrane receptors for P4 that were 
distinct from the classical nuclear progesterone receptor (nPGR). So, even if PGRMC1 
structure shares no homology with steroid receptors, researchers have always 
wondered if it could also exert some P4 related functions.  
 In 2015, Kaluka et al. definitely demonstrated by ultraviolet–visible and 
resonance Raman spectroscopies that P4 can interact with heme bound to an N-
terminally truncated bacterially expressed PGRMC1. Thus providing the strongest 
evidence for PGRMC1 binding P4 [177]. Nevertheless, P4 anti-apoptotic and anti-
proliferative action on rat granulosa cells and rat spontaneously immortalized 
granulosa cells (SIGCs) is the only demonstrated P4 action mediated by PGRMC1 
[154, 226] and a multiplicity of PGRMC1 function not related to P4 have been reported. 
 It is clear that more studies are needed to understand the precise mechanism 
of action through which PGRMC1 mediates P4 signaling.  The current hypothesis is 
that for this process both a cytoplasmic and a nuclear component are required. P4 
binds to cytoplasmic PGRMC1, which is likely on plasma membrane, and three 
cytoplasmic events could be involved in P4’s anti-apoptotic action: the induction of 
protein kinase G activity [227] and the suppression of Erk1/2activity [228], together with 
intracellular free calcium levels [229].  
 In addition, also a genomic function for PGRMC1 has been described, in which 
PGRMC1 mediates gene expression of certain genes. The genomic component of 
PGRMC1’s action, according to Peluso group studies, seems to involve PGRMC1 
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dimer in the nucleus, responsible for changes in gene expression profile to finally 
promote cell survival [175]. This signaling pathway could involve PGRMC1 binding to 
plasminogen activator inhibitor 1 mRNA-binding protein (PAIRBP1) [226], which is 
considered essential since P4 increases this interaction and depleting PAIRBP1 
attenuates P4’s ability to inhibit apoptosis [230]. 
 
 
From this overview, the multifunctional protein PGRMC1 is proposed to be a signaling 
nexus hub protein in the middle of a network of different functions, modulating several 
pathways in distinct organs and subcellular compartment according to different 
interactions with other molecules.  Moreover, PGRMC1 seems to be relevant to 
multiple diseases processes, making it an interesting protein to study in all its 
multiplicity and being considered a potential target for therapy/biological marker in 
disparate contexts [231] (Figure 3.5).  
 
 
 
 
Figure 3.5 PGRMC1 variety of functions supporting the hypothesis of a multifunctional 
protein changing its role according to its localization, structure and interaction with 
different molecules. From [231]. 
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4. Objectives of the thesis and significance 
 
 The main aim of this thesis project is to study the putative role of PGRMC1 as 
one of the key molecules involved in reproductive function. In particular, given the wide 
variety of localizations even within the same system and its numerous functions, there 
is the need to study its contribution relatively to each cell type and subcellular 
compartment to ultimately unravel PGRMC1’s role. 
 We propose that PGRMC1 has a role in bovine ovary during folliculogenesis, 
both in follicular cells compartment and in the oocyte. Our hypothesis is based on 
strong evidence supporting this protein being expressed in follicular cells and oocytes 
of many mammalian species (see PGRMC1 overview chapter).  
 Hence, in this PhD project firstly we focused on PGRMC1 putative contribution 
to cellular division, both in follicular granulosa cells and in the oocyte, as suggested by 
the dynamic localization of PGRMC1 in mitotic and meiotic spindle indicating a possible 
common function. We especially evaluated its role during the last phases of division 
including chromosome segregation, as this is one of the most important stages as seen 
before. 
 Since PGRMC1 could have a role in mediating P4 action both in follicular cells 
and in the oocyte, more experiments were conducted on investigating its role as a 
mediator of P4 action specifically during meiotic maturation and comparing its effect to 
nPGR putative non-genomic role in the oocyte.  
 In a second part of the project we extended our research to add more insight 
into the putative mechanism of action of PGRMC1 in cell division studying its possible 
role and mechanism of action in a specific nuclear region, the nucleolus, in bovine 
granulosa cells and in growing and fully grown oocytes.  
 Finally, since PGRMC1 role in cell proliferation could be relevant also in cancer 
biology we performed some preliminary studies on its role in tumors, considering the 
growing evidence and interest of its involvement in this disease. We described for the 
first time its expression in normal canine mammary gland and then its expression in 
three main different types of canine mammary cancer.  
 The importance of studying factors involved in reproduction and in particular in 
the quality of the gamete is relevant for dairy industry. PGRMC1 could be one of the 
key molecules to be used to overcome the infertility issue reviewed in the introduction, 
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which leads to economic losses and has an impact also on animal welfare. Moreover, 
besides likely improving assisted reproductive technologies in livestock, the results of 
our studies could be translated also for human reproduction unraveling causes and 
solutions for women infertility since PGRMC1 is already one of the proposed proteins 
involved in this problem. Finally, as PGRMC1 is becoming an interesting putative 
biomarker in cancer biology and our preliminary studies could add some new insight 
in this field as well.  
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5. PGRMC1 participates in late events of bovine granulosa cells mitosis 
and oocyte meiosis 
 
 
 
 
Foreword: 
This chapter is a published article. The original full paper is provided in the appendix. 
Terzaghi L, Tessaro I, Raucci F, Merico V, Mazzini G, Garagna S, et al.  
 PGRMC1 participates in late events of bovine granulosa cells mitosis  
 and oocyte meiosis. Cell Cycle. 2016;15(15):2019-32. 
 
 
 
 In this paper, we evaluated PGRMC1 role in meiotic and mitotic division. Our 
experimental approach mainly involved interfering with PGRMC1 expression and 
evaluating the effect on mitotic and meiotic division. On a primary cell line of bovine 
granulosa cells, we used small interfering RNA (RNAi) gene silencing technique and 
evaluated the effect on cell proliferation, further assessing the precisely mitotic phase 
which was most affected by using flow cytometry analysis and time-lapse imaging. 
While in in vitro matured bovine oocytes we impaired PGRMC1 function through RNAi 
downregulation and pharmacological inhibition using AG205. To further assess the 
involvement of PGRMC1 in the correct completion of division we evaluated its 
relationship with regulating proteins such as AURKB using immunofluorescence in 
both systems. 
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5.1 Abstract 
 
 Progesterone Receptor Membrane Component 1 (PGRMC1) is expressed in 
both oocyte and ovarian somatic cells, where it is found in multiple cellular sub-
compartments including the mitotic spindle apparatus. Strikingly, PGRMC1 localization 
in the maturing bovine oocytes mirrors its localization in mitotic cells, suggesting a 
possible common action in mitosis and meiosis. To test the hypothesis that altering 
PGRMC1 activity leads to similar defects in mitosis and meiosis, PGRMC1 function 
was perturbed in cultured bovine granulosa cells (bGC) and maturing oocytes and the 
effect on mitotic and meiotic progression assessed. RNA interference-mediated 
PGRMC1 silencing in bGC significantly reduced cell proliferation, with a concomitant 
increase in the percentage of cells arrested at G2/M phase, which is consistent with 
an arrested or prolonged M-phase. This observation was confirmed by time-lapse 
imaging that revealed defects in late karyokinesis. In agreement with a role during late 
mitotic events, a direct interaction between PGRMC1 and Aurora Kinase B (AURKB) 
was observed in the central spindle at of dividing cells. Similarly, treatment with the 
PGRMC1 inhibitor AG205 or PGRMC1 silencing in the oocyte impaired completion of 
meiosis I. Specifically the ability of the oocyte to extrude the first polar body was 
significantly impaired while meiotic figures aberration and chromatin scattering within 
the ooplasm increased. Finally, analysis of PGRMC1 and AURKB localization in 
AG205-treated oocytes confirmed an altered localization of both proteins when meiotic 
errors occur. The present findings demonstrate that PGRMC1 participates in late 
events of both mammalian mitosis and oocyte meiosis, consistent with PGRMC’s 
localization at the mid-zone and mid-body of the mitotic and meiotic spindle. 
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5.2 Introduction 
 
 Progesterone Receptor Membrane Component 1 (PGRMC1) is a multi 
functional protein that plays important roles in regulating mammalian ovarian function 
1, 2. Within the ovary, PGRMC1 is expressed and exerts a function in both somatic and 
germ cells 3-5. Its clinical relevance is indicated by studies showing that altered 
PGRMC1 expression correlates with defective follicular development and infertility in 
women 6-8.  
 Primary evidence that PGRMC1 has a fundamental role in ovarian somatic cells 
comes from in vivo studies in mice, in which conditional knockout of PGRMC1 in 
granulosa cells impairs antral follicle development 2, 9. Accordingly, in vitro studies 
using different ovarian cell lines have shown that depleting PGRMC1 expression 
suppresses cell proliferation 10-12. However, the mechanism of action by which 
PGRMC1 controls ovarian cell proliferation is poorly understood. 
 So far, PGRMC1 is known as a mediator of progesterone’s antiapoptotic action 
in ovarian cell lines 3, 13, 14. When apoptosis is induced by serum starvation in rat 
spontaneously immortalized granulosa cells (SIGCs), PGRMC1 mediates 
progesterone’s anti-apoptotic function, at least in part, through the regulation of the 
expression of apoptosis-related genes 13, 15. This genomic action is exerted by high 
molecular weight forms of PGRMC1 that localize to the nucleus of interphasic cells 13, 
15. However, PGRMC1 is also found in other sub-cellular compartments where it 
probably exerts additional functions. In particular PGRMC1 associates to the mitotic 
spindle 11, 16, 17, where it directly interacts with beta tubulin 11 suggesting a role in the 
regulation of mitosis. Immunofluorescence studies have shown that PGRMC1 changes 
its localization dynamically during mitosis: it associates with the spindle apparatus in 
metaphase, while it localizes to the midzone and the midbody in anaphase and 
telophase/cytokinesis 11. These studies indicate an involvement in mitosis, however 
the molecular mechanism by which PGRMC1 regulates mitosis has not been fully 
characterized and further studies are needed to better understand its function. 
 PGRMC1 is also expressed in oocytes of several mammalian species 3-5. 
Previous experimental evidence obtained in in vitro matured bovine oocytes supports 
the hypothesis that PGRMC1 regulates meiotic chromosome segregation during 
meiosis I 5, 18. In the period that spans from meiotic cell cycle reentry to metaphase II, 
also known as oocyte maturation, PGRMC1’s localization dramatically changes. 
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Specifically, PGRMC1 begins to associate with the condensing chromosomes after 
nuclear envelope break down and localizes to the centromeric region of the 
metaphasic chromosomes at Metaphase I (MI) and MII stage, while at 
Anaphase/Telophase I (Ana/Telo I) it concentrates between the separating 
chromosomes 5. Interestingly, in an oocyte model characterized by increased 
aneuploidy and embryonic developmental failure, PGRMC1 fails to properly associate 
with the MII chromosomes 18. Remarkably, PGRMC1 co-localizes with phosphorylated 
(active) form of AURKB in all the different stages of maturation 5, suggesting an 
interaction between the two proteins. However, as in the case of somatic cells mitosis, 
the precise role of PGRMC1 during oocyte meiosis is not known. 
 Strikingly, PGRMC1 localization in the maturing oocytes mirrors its localization 
in ovarian mitotic cells, suggesting a possible common function in both mitotic and 
meiotic cell division. The present study investigates the hypothesis that interfering with 
PGRMC1 function leads to similar defects in mitosis and meiosis in primary culture of 
bovine granulosa cells (bGC) and maturing bovine oocytes respectively. bGC were 
cultured in the presence of serum to stimulate cell growth and PGRMC1 function was 
altered using small interfering RNA (RNAi) mediated gene silencing approach. Bovine 
oocytes were in vitro matured and PGRMC1 function was impaired by using either a 
known PGRMC1 inhibitor (AG 205) 19 or RNAi. In addition, a possible relationship 
between PGRMC1 and AURKB has been investigated in both systems. 
 
 
 5.3 Materials and Methods 
 
 5.3.1 Reagents 
 All the chemicals were purchased from Sigma-Aldrich (St. Louis, MO) except 
for those specifically mentioned. Gene silencing was performed by Stealth RNAi™ 
siRNA technology from Life Technologies 
(https://www.lifetechnologies.com/it/en/home/life-science/rnai/synthetic-rnai-
analysis/stealth-rnai-technology.html?icid=cvc-invivo-sirna-c2t2). The ‘BLOCK-iT™ 
RNAi Designer’ tool from Life Technologies 
(https://rnaidesigner.lifetechnologies.com/rnaiexpress/) was used to design PGRMC1 
Stealth RNAi (PGRMC1 RNAi) within the coding region of the bovine PGRMC1 
sequence (NM_001075133). Sequence of the PGRMC1 RNAi used was:  (RNA)-GAG 
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UUG UAG UCA AGU GUC UUG GUC U. Negative control (cat n. 12935-200) was 
chosen among the Stealth RNAi negative control (CTRL RNAi) duplexes available from 
Life Technologies,. Stock solution of AG205 (16 mM) was prepared in Dimethyl 
sulfoxide (DMSO) and stored at -20C°.  Primary antibodies were: rabbit polyclonal anti-
PGRMC1 (Sigma, cat. HPA002877, lot number: A01099 and A27579), mouse 
monoclonal anti beta tubulin (Sigma, cat. T8328, clone AA2) and mouse monoclonal 
anti AURKB (BD transduction Laboratories, cat. 611082, clone 6/AIM-1). Primer pair 
sequences were synthetized from Primm s.r.l. (Milan, Italy). 
 
 5.3.2 Sample collection 
COCs were collected from pubertal Holstein dairy cows recovered at the abattoir 
(INALCA S.p.A., Ospedaletto Lodigiano, LO, IT 2270M CE, Italy) as previously 
described from of 2-6 mm ovarian antral follicles 5. Only medium-brown in color COCs, 
with five or more complete layers of cumulus cells and oocytes with finely granulated 
homogenous ooplasm were used.  
 After COC retrieval, the bGC were collected, washed and plated. Cells were 
cultured in growth medium, which was Dulbecco’s modified medium supplemented 
with 10% bovine calf serum, 100 U/ml of penicillin G, 100 µg/ml of streptomycin and 
1U/ml Glutamax (Gibco,Thermo Scientific), in humidified air at 37°C with 5% CO2. After 
24 h cells were washed with PBS, cultured in growth medium for 6-7 days until 
confluent, and then used according to the experimental design. 
 
 5.3.3 RNAi treatment 
 
bGC RNAi treatment 
 2 X 105 bGC were plated in 35-mm culture dishes. For immunofluorescence 
studies cells were plated on cover glasses, while for time-lapse experiments, glass 
bottom dishes (CELLview, Greiner bio-one) were used. After 24 h of culture (50-70% 
confluence), bGC were transfected with 6 µl of 20 µM PGRMC1 Stealth RNAi or CTRL 
RNAi combined with 10 µl of Lipofectamine® RNAiMAX Transfection Reagent 
(Thermo Fisher Scientific) in a final volume of 2 ml Opti-MEM® Reduced Serum 
Medium (Gibco, Thermo Fisher Scientific). Transfection efficiency, evaluated using the 
BLOCK-iT™ Alexa Fluor® Red Fluorescent Control (Invitrogen, Thermo Fisher 
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Scientific) and calculated as the number of red fluorescent cells on the total number of 
DAPI stained nuclei, was 80% after 24 h treatment and remained constant up to 72 h. 
 
Oocyte RNAi treatment 
 COCs were collected in medium supplemented with the 3-isobutyl-1-methyl-
xanthine (IBMX) at the final concentration of 0.5 mM, as previously described 20. 
Groups of 20-30 COCs were maintained meiotically arrested by adding 10 μM 
cilostamide as before described 21, 22 until microinjection (minimum 30 minutes). A 
microinjection apparatus (Narishige Co. Ltd.) mounted on an inverted microscope 
(Nikon Diaphot; Nikon Corp.) and a Femtojet microinjector (Eppendorf, Hamburg, 
Germany) were used to inject 10 pl of 20 µM PGRCM1 RNAi or CTRL RNAi into the 
ooplasm of COC. After injection, COCs were cultured with cilostamide overnight (the 
total treatment with cilostamide lasted 18 hours). COCs were then washed and in vitro 
matured for 24 h as previously described 23. 
 
 5.3.4 Treatment with AG205 
Groups of 15-20 COCs or denuded oocytes (DOs) were in vitro matured for 24 h with 
or without 10, 20 or 40 µM AG 205 19. To obtain DOs, oocytes were mechanically 
separated from cumulus cells as previously described 23, 24. The control group (0 µM 
AG205) was cultured with an equivalent amount of DMSO that was used to dissolve 
AG205. 
 
 5.3.5 Quantitative Reverse Transcriptase-polymerase chain reaction (qRT-PCR) 
 Oocyte’s total RNA was extracted with the Pico-Pure RNA Isolation Kit (Applied 
Biosystems) following the manufacturer’s protocol and including DNase treatment 
(Qiagen) on the purification column, while bGC total RNA was extracted with the 
RNeasy Mini Kit (Qiagen).  
 Total RNA was retro-transcribed (RT) with random hexamers using the First-
strand Synthesis System for RT-PCR System (Invitrogen, Life Technologies). 1 µg of 
bGC RNA or cDNA equivalent to 0.3 oocytes per reaction were used. Primer pairs are 
shown in supplemental table 1. SYBR green (Bio-Rad) was used according to the 
manufactures instructions and reactions were developed in an iQ5 PCR Thermal 
Cycler (Bio-Rad). Primer pairs specificity was assessed using standard RT-PCR and 
sequencing analysis. PGRMC1 relative expression level was analyzed with the ΔΔ-ct 
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method 25 using the HIS1H2A 26, 27 and/or GAPDH 28 as reference genes with the 
Biorad iQ5 Software. Data from 3 independent experiments were imported and 
grouped into a single ‘Gene Study’. 
 
 5.3.6 Western blot analysis  
 SDS-PAGE of bGC lysates was conducted as previously described 15. Briefly, 
PGRMC1 or CTRL RNAi treated bGC were lysed in radioimmunoprecipitation assay 
(RIPA) buffer Total amount of protein was determined using the Qubit® Protein Assay 
Kit and Qubit® fluorometer (Thermo Fisher Scientific). 20 µg of total protein/lane were 
used for Western blotting. 
 SDS-PAGE of oocytes was optimized to detect protein expression in small 
samples as previously described 29, 30. RNAi treated oocytes were denuded, washed 
and collected in 2 µl of PBS supplemented with proteases and phosphatase inhibitor 
cocktails. Samples were than mixed with 2 µl of 2X SDS–Laemmli loading buffer (Bio-
Rad), boiled for 5 min and stored at –80°C until essayed. After thawing, samples were 
boiled for additional 5 minutes and resolved on a 10% SDS-PAGE with a 4% stacking 
gel. Micro-wells in the stacking gel were 1mm in width, 0.5 mm in thickness and 10 mm 
height, contains a maximum volume of 5 µl. The comb for these micro wells was made 
with a 3-D printer in William Kinsey laboratory and kindly provided by Lynda McGinnis, 
University of Kansas Medical Center. 
 Run transfer and immunoblotting were performed as previously described 11 
using the anti PGRMC1  rabbit polyclonal antibody (1:200) . PGRMC1 was revealed 
using a goat anti rabbit IgG peroxidase conjugated antibody (1:1000, Thermo scientific, 
cat.32460) and detected using the Super Signal West Dura Extended Duration 
Substrate (Thermo scientific, cat.37071). The nitrocellulose membrane was stripped 
and re-probed with the anti beta tubulin antibody (1:1000) as before described 11, which 
was revealed using a stabilized goat anti mouse IgG peroxidase conjugated antibody 
(1:1000, Thermo scientific, cat.32430). Relative amount of protein was quantified on 
scanned films 31 using Image J software. The intensity of each PGRMC1 band was 
firstly normalized for the corresponding beta tubulin band and than the ratio between 
PGRMC1 RNAi and CTRL RNAi corresponding bands were calculated. PGRMC1 
expression in PGRMC1 RNAi treated oocytes was expressed as a percentage of the 
corresponding CTRL RNAi treated group. These values were pooled for statistical 
analysis. 
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 5.3.7 Assessment of bGC growth, effect on cell cycle and mitosis 
 After treatments, cells were collected after trypsinization. Care was taken to 
avoid loss of cells during collection and to ensure complete detachment of the cells 
from the plate by looking at the culture dishes under the microscope after trypsinization. 
Total cell number was counted with a Neubauer chamber. Cell growth rate was 
calculated as the ratio of the total number at each time point on the total cell number 
at the time of plating. Flow cytometry analysis was conducted in order to evaluate the 
percentage of cells at each cell cycle phase as previously described 32. Cells were 
collected, fixed in 70% cold EtOH and kept at +4°C until essayed. 
 For time-lapse analysis CTRL and PGRMC1 RNAi treated bGC were stained 
with 0.05 µg/ml of Hoechst 33342 for 30 minutes and then substituted with fresh 
medium and imaged on a biostation IM (Nikon). Images were captured every 5 minutes 
for 6 h after 30 h from treatment. Each time 6 different fields were captured at a 20X 
magnification. 
 
 5.3.8 Assessment of PBI extrusion and meiotic progression of bovine oocytes 
 After IVM, oocytes were denuded and examined under the stereomicroscope at 
the highest magnification (50 X) to assess complete extrusion of the PBI in the 
perivitelline space. Then, oocytes were fixed in 4% paraformaldehyde in PBS, 
permeabilizaed in 0.1% Triton-X 100 in PBS for 10 minutes and washed in 0.1% PVA 
in PBS (PBS/PVA). Samples were mounted on slides with the anti-fade medium 
Vectashield (Vector Laboratories) supplemented with 1 µg/ml 40,6-diamidino-2-
phenylindole (DAPI) to visualize DNA. Samples were analyzed on an epifluorescence 
microscope (Eclipse E600; Nikon Corp.) equipped with a digital camera (DS-Fi2; Nikon 
Corp.) to assess the stage of meiotic progression as previously described 18. 
 
 5.3.9 Immunofluorescence 
 Immunofluorescence analysis of PGRMC1 and AURKB localization were 
conducted as previously described on bGC grown on cover glasses 11 or denuded 
oocytes 5, 18 with minor modification. Briefly, after culture, washing and fixation 
procedures were conducted with pre-warmed media. Paraformaldehyde fixed samples 
were incubated overnight at 4°C with a combination of the rabbit anti-PGRMC1 
(dilution 1:50) and anti AURK B (dilution 1:50) antibodies. Secondary antibodies used 
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were: TRITC-labeled donkey anti-rabbit antibody (dilution 1:100; Vector Laboratories, 
Inc.) and Alexa Fluor 488-labeled donkey anti-mouse antibody (dilution 1:500; 
Invitrogen, Life Technologies) for 1 h at room temperature. The samples were mounted 
on slides in the antifade medium Vecta Shield (Vector Laboratories) supplemented with 
1 µg/ml 40,6-diamidino-2-phenylindole (DAPI). Samples were analyzed on an 
epifluorescence microscope (Eclipse E600; Nikon) equipped with a 60X objective, a 
digital camera, and software (NIS elements Imaging Software; Nikon). 
Immunofluorescence controls, which were performed by omitting one of the 2 primary 
antibodies while both fluorescently labeled secondary antibodies were present in all 
reactions, did not show any staining.  
 
 5.3.10 In situ Proximity Ligation Assay (PLA) 
 The interaction between PGRMC1 and AURKB was assessed using in situ PLA 
(Duolink II; OLINK Bioscience, Uppsala, Sweden http://www.olink.com/) in in vitro 
cultured bGC following the manufacturer protocol. Primary antibodies for PGRMC1 
and AURKB were the same used for immunofluorescence while anti-rabbit PLUS and 
anti-mouse MINUS PLA probes were used as secondary antibodies. Negative controls 
were performed omitting one of the two primary antibodies. Cells were mounted with 
Duolink mounting medium (OLINK Bioscience). Samples were analyzed as described 
for immunofluorescence and ImageJ software was used to calculate the total area of 
the fluorescent signal corresponding to proteins interaction during the different mitotic 
phases. 
 
 5.3.11 Statistical analysis  
 Experiments were run in triplicates, unless otherwise specified. All statistical 
analysis was done using GraphPad Prism software (GraphPad Prism v. 6.0e, La Jolla, 
CA, USA). Data from the replicate experiments were pooled and the data expressed 
as a mean ± SEM. Student’s t test was used to determine differences between two 
groups. When more than two groups were compared, one-way ANOVA followed by 
Tukey's Multiple Comparison test or two way ANOVA followed by Bonferroni post test 
were used. Fisher’s exact test was used to analyze percentage data. Details on the 
statistical analysis are indicated for each experiment in the figure caption. 
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5.4 Results 
 
5.4.1 PGRMC1 silencing affects bovine granulosa cells (bGCs) proliferation 
 
 To determine the effect of PGRMC1 silencing on the proliferation of cultured 
bGCs, cells were treated with PGRMC1 small interfering RNA (RNAi) or control (CTRL) 
RNAi and cultured for 24, 48 or 72 h in serum-supplemented medium to stimulate cell 
growth. Over the course of 72 h, treatment with PGRMC1 RNAi significantly reduced 
PGRMC1 mRNA levels compared to CTRL RNAi treated group, as assessed by 
quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR, figure 5.1 A). 
Western blot analysis confirmed the presence of multiple PGRMC1 bands, similar to 
what is observed in human and rat granulosa cells 15.  All the PGRMC1 band 
decreased at 72 h after PGRMC1 RNAi treatment (figure 5.1 B). Quantification of band 
revealed a significant overall 52.7 ± 10.9% reduction of PGRMC1 protein in RNAi 
treated cells compared to control cells (one sample t-test, p< 0.05).  
 To evaluate the effect of reduced PGRMC1 expression on bGC growth, cells 
were harvested at each time point and total cell number was counted. There were 
significanlty less cells in the RNAi PGRMC1 depleted group compared to CTRL RNAi 
treated group (figure 5.1 C). Moreover, flow cytometry analysis revealed that the 
decrease in total cell number after 72h of culture in PGRMC1 RNAi-treated bGCs was 
accompanied by a decrease in the frequency of G0/G1 stage cells and an increase in 
the frequency of cells arrested at G2/M phase of the cell cycle (figure 5.1 D and 
supplemental figure 5.1).  
 The decreased cell number and parallel increase in G2/M rates in PGRMC1 
RNAi treated bGC suggests a defective proliferation, which can be due to an arrested 
or prolonged M-phase of the cell cycle.  This hypothesis was confirmed using time-
lapse imaging, in which PGRMC1 and CTRL RNAi treated bGCs were stained with the 
supravital Hoechst 33342 fluorochrome and imaged every 5 minutes, for a total of 6 h. 
In these experiments, morphological evaluation of dividing nuclei throughout the 
course of mitosis revealed that cells treated with CTRL RNAi progressed from 
prophase to telophase giving rise to two daughter nuclei (figure 5.2 A and movie 5.1). 
In contrast, cells exposed to PGRMC1 RNAi started to divide but their further 
progression through the cell cycle was impaired and three main phenotypes were 
observed. In the first phenotype, cells undergo prophase/metaphase but do not 
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progress beyond the Ana/Telo phase, reforming a single nucleus (figure 5.2 B and 
movie 5.2); in the second phenotype, cells undergo prophase/metaphase and 
progress through the following stages in an irregular manner that lead to the formation 
of aberrant nuclei (movie 5.3), in which small clumps of DNA remain excluded from 
the reforming nuclei while, in the third phenotype, cells undergo prophase/metaphase 
but DNA remains interconnected through the following stages leading to incomplete 
karyokinesis  (movie 5.4). Collectively, we defined these phenotypes as ‘abnormal 
mitosis’ since they differed from the phenotype observed in CTRL RNAi treated bGC. 
As shown in figure 5.2 C nearly 70% of the PGRMC1 RNAi treated cells that started 
dividing showed these morphological alterations of mitotic progression. We can 
assume that errors leading to the first phenotype occurred earlier during meiotic 
progression when compared to the second and the third phenotypes. Interestingly, the 
sum of phenotype 2 and 3 represented the majority of ‘abnormal’ mitosis (78.9%) 
suggesting that PGRMC1 RNAi treatment mostly affected events occurring during late 
mitosis.  
 Moreover, the duration of cell cycle progression, from the beginning of prophase 
to the formation of two daughter nuclei, was significantly increased (figure 5.2 D). As 
expected, under these experimental conditions (i.e. culture in serum), cellular death of 
non-mitotic cells was low in both CTRL and PGRMC1 RNAi treated bGC (2.37 ± 0.42 
and 2.41± 0.65 % on a total of 1585 and 1209 observed cells, respectively).  Therefore, 
apoptosis does not likely account for the lower cell number observed in PGRMC1 
depleted cells. 
 
 5.4.2 PGRMC1 co-localizes and interacts with Aurora kinase B during bGC  
 mitosis. 
 
 Since cell division is dependent on Aurora kinase B (AURKB) 33-35, we 
performed double immunofluorescence staining to examine the relationship between 
the localization of AURKB and PGRMC1 during bGC mitosis.  As shown in figure 5.3, 
the two proteins colocalize, particularly during telophase. Furthermore, in situ Proximity 
Ligation Assay (PLA) was conducted to test whether PGRMC1 directly interacts with 
AURKB during the different stages of mitosis. This technique uses a pair of 
oligonucleotide-labeled secondary antibodies (PLA probes), which generate a signal 
only when the two probes have bound in close proximity. The signal from each 
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detected pair of PLA probes is visualized as an individual fluorescent spot. As shown 
in figure 5.4 A, PLA revealed an interaction between AURKB and PGRMC1.  
Moreover, the degree of interaction, evaluated as the mean of the total fluorescence 
area in each mitotic cell, was low from prophase to anaphase and then increased 
significantly at telophase (figure 5.4 B).  
 
 5.4.3 Pharmacological inhibition of PGRMC1 function during bovine oocyte 
 meiosis impairs karyokinesis and polar body emission  
 
 During meiosis I, homologue chromosome segregation and cytokinesis are 
spatiotemporally coordinated in order to ensure the proper ploidy but asymmetric 
cytoplasmic division between the MII oocyte and the first polar body (PBI) (reviewed in 
36). To determine whether PGRMC1 plays a role in PBI cytokinesis, cumulus cell-
oocyte complexes (COCs) and denuded oocytes (DOs) were cultured in in vitro 
maturation (IVM) medium in the presence or absence of increasing concentrations of 
the PGRMC1 inhibitor AG 205 19. After culture, the effect on PBI emission was 
evaluated under bright field microscopy, while the effect on chromosome segregation 
was assessed under epifluorescence microscopy after fixation and DNA staining. 
 As shown in figure 5.5, PBI extrusion rate decreased when COCs or DOs were 
cultured with 20 and 40 µM AG205 compared to the control group (0 µM, P<0.05). This 
effect was more pronounced in DOs, where PBI formation was already lower with 10 
µM AG205. As shown in figure 5.6, AG205 treatment also impaired chromosome 
segregation determining a decrease in the percentage of oocytes that reached the MII 
stage and an increase in oocytes showing aberrant meiotic figures. In particular, these 
aberrancies included the presence of DNA clumps scattered within the ooplasm 
(figure 5.6 A, aberrant) as well as the coexistence of two metaphase plates or 
telophases (these examples of aberrant meiotic figures observed after AG205 
treatment are shown in supplemental figure 5.2). Oocytes in which the DNA was 
collapsed into a single clump, or in which DNA was not detectable within the ooplasm, 
were classified as degenerated. Sample observation under bright field combined to UV 
light illumination confirmed the correct analysis of DNA clumps localization within the 
ooplasm (supplemental figure 5.3). The effect of AG205 appeared more pronounced 
in DOs (figure 5.6 C).  
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 Finally, in order to assess whether AG205 treatment affected AURKB 
localization, PGRMC1 and AURKB localization was assessed in AG205 treated COCs 
by double immune fluorescence experiments. PGRMC1 and AURKB localization in the 
oocytes was classified as regular or irregular according to the previously published 
criteria 18. Localization was judged as regular when the proteins localized at the 
centromeric region of each chromosome or irregular when one or more of the following 
configurations was observed: more than one point on a chromosome, shape different 
from the punctuated, not in the centromeric region, and/or lack of signal. As shown in 
figure 5.7 aberrant meiotic figures showed irregular AURKB and PGRMC1 
localization, while both PGRMC1 and AURKB showed a focused centromeric 
localization in oocytes with MII plate.  
 
 5.4.4 RNAi mediated PGRMC1 silencing during oocyte maturation mirrors AG205  
 effects impairing karyokinesis and polar body emission 
 
 PGRMC1 function in oocytes was also assessed by microinjecting RNAi into 
germinal vesicle (GV) stage oocytes surrounded by cumulus cells. After microinjection 
with either CTRL or PGRMC1 RNAi and culture for 18 h under in vitro meiotic arrest 
conditions (IVA), allowing sufficient time for the RNAi to effectively deplete the gene of 
interest, oocytes were cultured in IVM medium for further 24 h. Preliminary optimization 
experiments in which a fluorescent tracker was used to assess microinjection efficiency 
indicated that »80% of the oocytes were successfully microinjected. Moreover, survival 
rate, assessed as the percentage of viable COCs after IVA, did not differ in CTRL and 
PGRMC1-RNAi microinjected COCs (96.06±2.10 and 96.23±2.73% respectively, 
p>0.05 t-test, n=11 independent experiments) 
  As reported in figure 5.8A-C, PGRMC1 mRNA and protein were reduced 
approximately by 40% as assessed by qRT-PCR and Western blotting, respectively.  
Depleting PGRMC1 significantly reduced the percentage of oocytes that extruded the 
PBI (figure 5.8 D). Moreover, fluorescence microscopy analysis revealed that even 
though the formation of MII plate was not blocked in PGRMC1 RNAi-treated oocytes, 
there was an increase in the frequency of oocytes with aberrant meiotic figures (figure 
5.8 E and F), which were similar to that observed after AG205 treatment. Additional 
		 51	
examples of aberrant meiotic figures upon PGRMC1 RNAi treatment are shown in 
supplemental figure 5.4. 
 
5.5 Discussion 
 
 Proper completion of cell division is an essential process in both somatic and 
germ cells. In somatic cells, after DNA replication and sister chromatids separation, 
cytokinesis ensures that the genetic material as well as the cytoplasmic organelles are 
evenly distributed into two daughter cells 37.  In contrast, cell division in oocytes allows 
for the elimination of half of the genetic material through PB emission while retaining 
most of the cytoplasm to support the early stages of embryo development. Extrusion 
of the PB is essential for the formation of the mature egg 36, 38. Nonetheless late mitotic 
and oocyte meiotic division share many similarities 36. In both systems, microtubules 
of the anaphase spindle play important roles in the formation of the actino-myosin 
contractile ring and the formation of the cytokinetic furrow at this site, allowing the 
physical separation of the two daughter cells (reviewed in 36). Moreover, the essential 
role of the chromosomal passenger complex (CPC) in orchestrating late mitotic events 
33, 34 is likely conserved in meiosis 39-42. 
 The present study adds new insights into the role of PGRMC1 as a regulator of 
both mitotic and meiotic cell division. Our data indicate that when PGRCM1 function is 
impaired both somatic cells and oocytes fail to divide properly. Specifically, knocking 
down PGRMC1 by RNAi in cultured bGC results in the inability to successfully 
complete mitosis and/or to form two normal nuclei in dividing cells. Similarly, in the 
maturing oocytes, perturbing PGRMC1 function by using pharmacological or RNAi 
approaches results in the impairment of polar body emission together with the 
formation of aberrant meiotic figures. As a result, a second metaphasic plate and/or 
scattered chromatin are usually observed.  
 Previous works demonstrate that PGRMC1 specifically localizes to the mitotic 
spindle apparatus of different cell lines 11, 16, 17, where it directly interacts with beta 
tubulin and controls spindle microtubule stability 11. The present study demonstrates 
also that PGRMC1 directly interacts with AURKB and that the extent of this interaction 
is highest during the final phase of granulosa cell division. This is important since 
events occurring at the central spindle during the formation of the midbody are crucial 
for proper cell division. For example, the central spindle plays an important role in 
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keeping separated chromosomes apart prior to cytokinesis completion, because when 
microtubules are depolymerized in late anaphase, the nuclei collapse back together 43, 
44. Thus our findings may suggest that an additional mechanism by which PGRMC1 
controls mitosis involves a direct interaction with AURKB at the mid-body. This concept 
is consistent with the finding that interfering with PGRMC1 function affects the 
localization of AURKB in oocytes that failed to properly complete meiosis. Furthermore, 
previous studies in bovine oocytes reveal that altering AURKB function by using the 
AURKB inhibitor ZM447439 also alters PGRMC1 localization, which was associated 
with meiotic defects 18. Thus PGRMC1 and AURKB functional association seems to 
be reciprocal, at least in the oocyte. However, the precise mechanism of action by 
which PGRCM1-AURKB interaction affects AURKB and CPC function remains to be 
elucidated. PGRMC1 could act as an adaptor protein in many different biological 
processes as proposed by Aizen et al 45. If this hypothesis were confirmed, PGRMC1 
action would depend on the proteins with which it interacts in different cellular and 
subcellular systems. In this view, altering PGRMC1 function in our studies could have 
had an effect on different effector proteins, such as AURKB and other CPC 
components, in the spindle midzone/midbody, thereby determining 
kariokinesis/cytokinesis disturbance and/or failure. However, this hypothesis remains 
to be confirmed.  
 Most probably, the fate of PGRMC1 depleted granulosa cells that do not 
properly complete cell division would be cellular death, which would contribute to the 
lower proliferation observed in PGRMC1 RNAi treated cells. This is consistent with 
effects of depleting PGRMC1 in SIGCs, where cells accumulate in metaphase and 
then undergo cell death 12. Another possible outcome of cytokinesis failure is the 
formation of bi- or multi-nucleated cells.  This is not the case for bGCs since 
multinucleated granulosa cells were not observed in PGRMC1 RNAi treated cells (data 
not shown).  
 Cell death resulting from aberrant mitosis is generally referred to as ‘mitotic 
catastrophe’ 46. Interestingly, this phenomenon has been functionally re-defined as an 
‘atypical mechanism that sense mitotic failure and respond to it by driving the cell to 
an irreversible fate, be it apoptosis, necrosis or senescence’ 47, 48. Thus, it has been 
proposed that mitotic catastrophe can be considered as an ‘onco-suppressive 
mechanism for the avoidance of genomic instability’ 47. Our time-lapse fluorescent 
microscopy experiments suggest that mitotic catastrophe might occur in PGRMC1 
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depleted bGC. This finding is in accordance with the experimental evidences that 
PGRMC1 depletion suppresses cancer cells proliferation in vitro and tumor growth in 
vivo in all the types of cancers studied so far 10, 19, 49-51. Moreover, the observation that 
PGRMC1 is overexpressed in a wide range of tumors when compared to 
corresponding normal tissues 19, 52-55 further support this hypothesis. In this view 
PGRMC1 overexpression would sustain propagation of abnormal cancer cell, helping 
them to escape mitotic catastrophe. However, further analyses are required to confirm 
this hypothesis. 
 It is possible that, in previous studies, the involvement of PGRMC1 in mitotic 
catastrophe events has been underestimated. In these studies, indeed, end-point 
methods have been used to assess the effect of PGRMC1 silencing. Clearly, end-point 
methods are inappropriate to detect this phenomenon, as they do not take into account 
the ‘history’ of the cell death 47. On the contrary, time lapse-imaging used in the present 
study overcomes this limitation giving experimental evidences for the first time of a 
possible involvement of PGRMC1 in mitotic catastrophe events, which must be deeply 
investigated in future studies. 
 Similarly, it is likely that oocytes that fail to extrude PBI and form aberrant 
meiotic figure would not undergo fertilization and/or second meiotic division, thus 
degenerate. In a previous study, injecting a PGRMC1 antibody into the ooplasm of 
immature bovine oocytes revealed a role for PGRMC1 in bovine oocyte maturation 5 
impairing the transition from pro-MI to MI stages with the majority of the oocytes 
arresting at the pro-MI stage. Only a very small percentage of oocytes reached MII, 
thus obscuring a putative PGRMC1 function during the final phase of oocyte 
maturation.  In the present study the use of RNAi gene silencing and a specific 
PGRMC1 inhibitor, AG205 reveals a role for PGRMC1 during the final phase of 
maturation (MI to MII transition).  In particular, the RNAi study clearly indicates that 
PGRMC1 is required to allow proper PBI emission. That PGRMC1 RNAi was effective 
also suggests that PGRMC1 is translated during this period. Moreover, it is known that 
PGRMC1 can undergo post-translational modifications such as phosphorylation and 
sumoylation 15, 53.  Whether translational regulation and/or post-translational 
modifications are involved in the mechanism that ensures a proper localization of 
PGRMC1 during oocyte maturation remains to be established. 
 AG205 experiments have been conducted on both COCs and DOs because 
cumulus cells also express PGRMC1 4, 56, 57. The observation that AG205 was more 
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effective on DOs than COCs confirms PGRMC1’s specific role within the oocyte. 
AG205 is a small aromatic compound that acts as a PGRMC1 ligand. It has been used 
to functionally assess PGRMC1 activity in several biological systems including 
mammalian cells with effective concentrations in the µM range 19, 45, 58. It was originally 
identified as a ligand for AtMAPR2 of the Arabidopsis thaliana 59, which shares 
homology with the cytochrome b5/heme binding domain of PGRMC1 1, 19, 59. Thus, 
although the precise biochemical mechanism through which AG205 inhibits PGRMC1 
activity is not known, it likely acts by binding to PGRMC1’s heme-binding domain, 
thereby disrupting PGRMC1’s ability to interact with yet to be identified heme proteins. 
This hypothesis is supported by the experimental evidence that AG205 alters the 
spectroscopic properties of the PGRMC1-heme complex 19.  Thus, it is likely that the 
PGRMC1 heme binding domain is an important component in the mechanism by which 
PGRMC1 regulates meiosis.   
 In conclusion the present findings reveal a new role of PGRMC1 in late stages 
of the mitotic division and oocytes meiosis. This function is consistent with the 
localization at the mid-zone and mid-body of the mitotic and meiotic spindle. To the 
best of our knowledge this is the first study that reveals a role of PGRMC1 during late 
mitotic and meiotic events and represents an advancement of the state of the art in the 
field by giving information of a precise stage of cell division in which PGRMC1 exerts 
a function.  Furthermore, PGRMC1’s action possibly involves a direct interaction with 
AURKB, as revealed by PLA studies. Importantly this function seems to be conserved 
in mammalian cell mitosis and oocyte meiosis. Thus this observations provides a 
strong rationale for future studies on the precise mechanism of PGRMC1’s action in 
the female gamete, in which technical limitation do not allow mechanistic conclusions, 
especially in large animal species. For example, since PGRMC1 exists in multiple 
forms (monomer and specific higher molecular weight forms and post translational 
modifications, 15, 53) in future studies it will be important to assess which of these 
modifications have a predominant role in regulating PGRMC1 function during final 
karyo/cytokinesis and are important in targeting PGRMC1 to specific sites within the 
different subcellular domains. Moreover, since PGRMC1 is a mediator of P4 actions, 
further studies would be needed to address whether and how PGRMC1 function at this 
particular site of action is mediated by P4. 
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5.6 Figure and supplemental movies  
 
5.6.1 Figures 
 
 
 
Figure 5.1: Effect of RNAi mediated PGRMC1 silencing on bGC growth. (A) Graph 
showing PGRMC1 mRNA silencing in PGRMC1 RNAi treated bGC as assessed by 
qRT-PCR. PGRMC1 expression level was normalized using GAPDH as reference 
gene. Data were analyzed by one way ANOVA, followed by Tukey's Multiple 
Comparison Test, Values are means ± SEM (n=3). * indicates significant differences 
between groups (P<0.05). (B) Representative Western blot showing the decreased 
expression of all PGRMC1 bands at 72 h in PGRMC1 RNAi treated bGC; beta tubulin 
was used as loading control. (C) Graph showing the effect of PGRMC1 down regulation 
on cell growth. Data were analyzed by two way ANOVA followed by Bonferroni post-
hoc test. Values are means ± SEM (n=3). * indicates significant differences between 
groups P<0.05. (D) Graph showing the increase in the percentage of cells arrested at 
G2/M phase after 72 h from transfection, as assessed by flow cytometry analysis. Data 
were analyzed by unpaired Student’s t-test, Values are means ± SEM (n=3). * indicates 
significant differences between groups (P<0.05). 
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Figure 5.2: Effect of PGRMC1 silencing on bGC mitosis by time-lapse analysis 
of transfected bGC. (A) Example of normal mitosis occurring in bGC transfected with 
CTRL RNAi. The cell goes through all the mitotic phases from prophase to telophase 
giving rise to two daughter nuclei (see supplemental movie 5.1). (B) Example of 
abnormal mitosis in bGC transfected with PGRMC1 RNAi, in which the cell starts the 
division process undergoing prophase but then fails to proceed beyond the 
Ana/Telophase (see supplemental movie 5.2). Additional examples of abnormal 
mitosis occurring in PGRMC1 RNAi treated bGC are shown in supplemental movies 
5.3 and 5.4. (C) Graph showing the frequency of normal and aberrant mitotic events 
assessed in CTRL and PGRMC1 RNAi treated cells. Data were analyzed by Fisher 
exact test. * indicates significant differences between groups P< 0.05. (D) Graph 
showing the time to complete mitosis in CTRL and PGRMC1 RNAi treated cells. Data 
were analyzed by unpaired Student’s t-test, * indicates significant differences between 
groups (P<0.05). This experiment was replicated four times; the total number of cells 
analyzed is shown in brackets. 
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Figure 5.3: Colocalization PGRMC1-AURK B in bGC. Representative images 
showing PGRMC1 (red) and AURKB (green) colocalization during the different mitotic 
phases of cultured bGC; DNA was stained with DAPI (blue). PGRMC1 and AURKB 
start to colocalize to the mitotic spindle region during prophase and the colocalization 
is more pronounced in the central spindle during ana/telophase. Scale bar is 10µm. 
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Figure 5.4: Interaction between PGRMC1 and AURKB during mitosis in bGC.  (A) 
Representative images of bGC showing PGRMC1 - AURKB interaction as assessed 
by In situ proximity ligation assay (PLA) from prophase until telophase. DNA was 
stained with DAPI (white). The red spots indicate PGRMC1-AURKB interactions. Scale 
bar is 10 µm. (B) Graph showing the increased interaction between these two proteins 
during telophase. Data were analyzed by one way ANOVA followed by Tukey's Multiple 
Comparison Test. Values are means ± SEM; * indicates significant differences 
between groups (P<0.05). This experiment was replicated three times with the total 
number of cells analyzed shown in brackets.  
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Figure 5.5: Effect of AG205 treatment on PBI emission.  (A) Representative images 
showing in vitro matured oocytes with (left, arrow) or without (right) extruded PBI. (B, 
C) Graphics showing the effect of AG205 treatment on the percentage of oocytes that 
extruded the PBI in COC and DO, respectively. Data were analyzed by one way 
ANOVA followed by Tukey's Multiple Comparison Test. Values are means ± SEM 
(n=3); a,b different letters indicate significant differences between groups (P < 0.05).  
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Figure 5.6: Effect of AG205 treatment on meiotic progression.  (A) Representative 
images showing oocytes classified as MI, Ana/Telophase, MII, aberrant or 
degenerated after AG205 treatment. Aberrant mitotic figure shown in this figure is 
characterized by the presence of DNA scattered within the ooplasm (arrow), while 
additional examples of aberrant meiotic figures observed after AG205 treatment are 
shown in supplemental figure 5.1. DNA was stained with DAPI (white). Scale bar is 
50 µm. Insets show the DNA at 2X magnification. Graphs in (B) and (C) show the 
percentages of oocytes at each stage of the first meiotic division (shown in A) in COC 
and DO respectively. Data were analyzed by one way ANOVA followed by Tukey's 
Multiple Comparison Test. Values are means ± SEM (N=3); a,b different letters indicate 
significant differences between groups (P < 0.05).   
		 61	
 
 
Figure 5.7: Effect of PGRMC1 AG205 on PGRMC1 and AURKB localization.  
Representative images showing PGRMC1 and AURKB localization in MII plates of 
matured oocytes or in oocytes showing aberrant meiotic figures. COC were treated 
with 0 or 20 µM AG205 for 24 h. After AG205 treatment oocytes were fixed, 
immunostained with anti- PGRMC1 (red) and AURKB (green) antibodies; DNA was 
stained with DAPI (blue). A total of 97 oocytes from 2 independent experiments were 
analysed. Both PGRMC1 and AURKB showed a focused centromeric localization in 
oocytes with MII plate, while they often showed a more diffused localization in aberrant 
meiotic figures with scattered chromosomes. When clumps of chromatin were present 
within the ooplasm, none of them were associated with AURKB and / or PGRMC1. 
Finally, when double meiotic plates were present, both AURKB and PGRMC1 showed 
a focused localization on metaphasic chromosomes of both plates. 
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Figure 5.8: Effect of PGRMC1 RNAi treatment on PGRMC1 expression level, PBI 
extrusion and meiotic progression.  (A) Graph showing PGRMC1 mRNA 
expression level in CTRL and PGRMC1 RNAi treated oocytes by RT-qPCR;  PGRMC1 
expression level was normalized using GAPDH and HIST1H2A as reference genes 
and differences in gene expression levels were assessed with the Delta-Delta Ct 
method. Data were analyzed by Student’s t-test. Values are means ± SEM (N=3); * 
indicates significant differences between groups (P < 0.05). (B and C) graph and 
representative western blotting showing PGRMC1 protein expression levels in CTRL 
and PGRMC1 RNAi treated oocytes; beta tubulin was used as loading control. 
PGRMC1 protein expression in PGRMC1 RNAi treated oocytes is expressed as a 
percentage of the CTRL RNAi treated group. Data were analyzed by one sample t-
test. Values are means ± SEM (n=6). * indicates significant differences (P < 0.05). (D) 
Graph showing the percentage of oocytes that extruded the PBI after CTRL or 
PGRMC1 RNAi treatment and IVM. Data were analyzed by t-test. Values are means ± 
SEM (n=14); * indicates significant difference between groups (P < 0.05). (E) Graph 
showing the percentage of oocytes showing aberrant meiotic figures. Data were 
analyzed by t-test. Values are means ± SEM (n=6); * indicate significant differences 
between groups (P < 0.05).  Image in (F) is representative of an aberrant meiotic figure 
observed after PGRMC1 RNAi treatment, in which chromosomes and DNA clumps are 
dispersed in the ooplasm and not organized in a MII plate (additional examples of 
aberrant meiotic figures are shown in supplemental figure 3). Scale bar is 50 µm. Insets 
show the DNA at 2X magnification.  
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5.6.2 Supplemental movies  
 
All the movies can be downloaded at their corresponding links: 
 
Supplemental Movie 5.1: time lapse of normal mitosis occurring in bGC transfected 
with CTRL RNAi shown in figure 5.2A. Cell progress from prophase to telophase giving 
rise to two daughter nuclei.  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968956/bin/kccy-15-15-1192731-
s002.mov 
 
Supplemental Movie 5.2: time lapse of abnormal mitosis occurring in bGC transfected 
with PGRMC1 RNAi, shown in figure 5.2B. Cell undergoes prophase/metaphase but 
does not progress beyond the Ana/Telo phase, reforming a single nucleus 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968956/bin/kccy-15-15-1192731-
s003.m4v 
 
Supplemental Movie 5.3: time lapse of abnormal mitosis occurring in bGC transfected 
with PGRMC1 RNAi. Cell undergoes prophase/metaphase and progressed through 
the following stages in an irregular manner leading to the formation of aberrant nuclei, 
in which small clumps of DNA remained excluded from the reforming nuclei while 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968956/bin/kccy-15-15-1192731-
s004.mov 
 
Supplemental Movie 5.4: time lapse of abnormal mitosis occurring in bGC transfected 
with PGRMC1 RNAi. Cell undergoes prophase/metaphase but DNA remained 
interconnected through the following stages leading to incomplete karyokinesis. 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4968956/bin/kccy-15-15-1192731-
s005.mov  
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5.7 Supplementary material 
 
5.7.1 Supplemental tables 
 
Supplemental table 5.1: Primer pair sequences used in q-RT PCR experiments 
 
Gene	 Oligo	Sequence	(5'-3')	
Prod.	
size	
(Bp)	
PCR	
Efficiency	
and	r^2	
Reference	
PGRMC1	
GCCTTTGCATCTTTCTGCTC	
195	 E=102.2	%;	r^2=	0.98	
Primer	3	
design;	
NM_00107513
3	TGGTTACGTCGAACACCTTG	
GAPDH	
CCAACGTGTCTGTTGTGGATCTGA	
218	 E=100.2	%;	r^2=	0.99	
Assidi	et	al.,	
BOR	2008	
79:209;	
NM_00103403
4	
GAGCTTGACAAAGTGGTCGTTGAG	
HIST1H2A	
(variant	H,	
C,	G)	
GTCGTGGCAAGCAAGGAG	
182	 E=109.7	%;	r^2=	0.97	
Robert	et	al.,	
BOR	2002	
76:1465;	
Vigneault	et	
al.,	MRD	2007	
74:703;	
LOC616634,LO
C506900;	
LOC616790	
GATCTCGGCCGTTAGGTACTC	
 
  
		 65	
5.7.2 Supplemental figures 
 
 
Supplemental figure 5.1: Representative DNA histograms generated by flow 
cytometric analysis of PGRMC1 and CTRL RNA1 treated bGCs after 72 h of 
culture. The difference in the G2/M phase is clearly appreciable. Note that the 
presence of debris at the left of the histogram in both groups is due to the nature of the 
sample analyzed.  
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Supplemental figure 5.2: Aberrant meiotic figures in AG205 treated oocytes 
Images show examples of aberrant meiotic figures observed after AG205 treatment. 
Images in a and b represent oocytes showing double Metaphase (a) or Telophase (b, 
note that b’ and b’’ are different focal planes of the same oocyte). Images c, d, e and f 
show oocytes with DNA clumps scattered within the ooplasm (note that f’, f’’ and f’’’ are 
different focal planes of the same oocyte and lighter stained areas are out of focus 
clumps of chromatin). Scale bar is 50 µm. Insets show the DNA at 2X magnification. 
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Supplemental figure 5.3. Representative images of DAPI stained oocytes under 
bright field. Samples were concomitantly illuminated with white and UV light using the 
DAPI filter, in order to ensure correct analysis of DNA clumps localization within the 
ooplasm.  
 
 
 
Supplemental figure 5.4: Aberrant meiotic figures in PGRMC1 RNAi treated 
oocytes Images show examples of aberrant meiotic figures observed after PGRMC1 
RNAi treatment. Image a shows an oocyte with a Telophase and additional DNA 
clumps. Images b to i show oocytes with DNA clumps scattered within the ooplasm. In 
some of these oocytes (g, h, i) the occurrence of scattered DNA was concomitant to 
the presence of a metaphase plate. Scale bar is 50 µm. 
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6. Role of Progesterone and its receptors Nuclear Progesterone 
Receptor (nPGR) and Progesterone Receptor Membrane Component 1 
(PGRMC1) in oocyte meiosis 
 
Foreword 
 
 This study was in part conducted during my period of PhD externship in Prof. 
Trudee Fair laboratory at University of Dublin. In this study, we compared PGRMC1 
and nPGR action in oocyte meiosis through their pharmacological inhibition using 
AG205 and Aglepristone, respectively, evaluating the effect on meiotic MII plates and 
tubulin spindle morphology.  
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6.1 Introduction  
 
 P4 has a role in both follicular cells and in the oocyte during maturation. Yet its 
mechanism of action is still unknown and some receptors other than the classical 
nPGR have been described. Specifically, in bovine both oocyte and cumulus cells 
express nPGR as well as the non-genomic receptors (PGRMC1, PGRMC2 and 
Membrane Progestin Receptors) in a cell-dependent way (oocyte-cumulus cells) and 
they dynamically change in in vitro maturation and after LH, FSH or P4 
supplementation [1-3]. 
 The functional importance of P4 and its receptors has started to be elucidated 
by experiments inhibiting cumulus cells P4 synthesis and blocking nPGR signaling 
using Trilostane and RU486, respectively, resulting in a significative reduction of 
blastocyst developmental rate [1, 4, 5]. Previous studies also demonstrated that 
RU486 impaired oocyte maturation in a dose-dependent manner [6]. On the other 
hand, PGRMC1 appears to be involved in meiotic maturation since intracytoplasmic 
injection of oocytes with an antibody against PGRMC1 affected chromosome 
segregation during oocyte meiotic maturation [2], while adding an antibody specific to 
mPRα during IVM reduced the percentage of oocytes progressing through the early 
cleavage stages [1]. However, the precise mechanism through which these receptors 
could mediate P4 actions remains to be elucidated together with their relative 
contribution during oocyte maturation and the consequent stages until embryogenesis, 
considering their function could be species-specific or be relative to different levels of 
P4 and combined expression of its receptors. 
 Both PGRMC1 and nPGR localize to chromosomes in Metaphase II plate of 
bovine oocytes and according to previous studies they could have a role predominantly 
in meiotic maturation and on subsequent embryo development, respectively [1, 2]. 
 
 Therefore, the main aim of this study is to decipher the role of progesterone 
receptors in meiotic maturation of bovine oocytes disrupting their function through 
inhibition of nPGR and PGRMC1. To inhibit nPGR we used both RU486 and 
Aglepristone. The PGRMC1 function was inhibited by AG205, as previously described 
[7].  
 Aglepristone blocks nPGR-mediated P4 effects and has a relative binding 
affinity equal to that of RU486 for the receptor, but has >9 times greater affinity than 
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that of P4 [4], while AG205 interacts with cytochrome b5/heme-binding domain of 
PGRMC1 which is the site interacting with various proteins and possibly also P4 [8].  
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6.2 Material and methods 
 
6.2.1 Samples collection and in vitro maturation 
Bovine ovaries were collected from a local abattoir in Ireland or Italy and immature 
COCs were collected from 2-6 mm antral follicles and in vitro matured as previously 
described [2, 7]. Groups of 20-25 COCs were matured for 24 hours in IVM medium 
supplemented with different concentrations of Aglepristone – (RU534/Alizin virbac, 0,1 
– 1 – 10 – 25 and 50 µM concentrations), RU486 – (SIGMA, 1 – 10 - 25 and 50 µM) or 
AG205 - (SIGMA, 20µM final concentration) or without the inhibitors. We also included 
a solvent control group adding only DMSO (10 µM concentration). 
 
 
6.2.2 Assessment of meiotic progression of bovine oocytes 
 
 The oocytes were denuded, fixed in 4% paraformaldehyde in PBS and 
permeabilized in 0.1% Triton-X 100 in PBS for 10 minutes and washed in 0.1% PVA 
in PBS (PBS/PVA). Samples were mounted on slides with the anti-fade medium 
Vectashield (Vector Laboratories) supplemented with 1 mg/ml 4’,6’-diamidino-2-
phenylindole (DAPI) to visualize DNA. Samples were analyzed on an epifluorescence 
microscope (Eclipse E600; Nikon Corp.) equipped with a digital camera (DS-Fi2; Nikon 
Corp.) to assess the stage of meiotic progression as previously described [7]. 
 
6.2.3 Meiotic spindle and metaphase II plate morphological assessment  
 
 For tubulin spindle length analysis oocytes were fixed in microtubule-stabilizing 
buffer (100 mM PIPES, 5 mM MgCl2, 2.5 mM EGTA, 2% formaldehyde, 0.1% Triton-
X-100, 1 mM taxol, 10 U/ml aprotinin and 50% deuterium oxide) for 30 min at 37°C 
and stored in blocking solution (0.2% sodium azide, 2% normal goat serum, 1% BSA, 
0.1 M glycine and 0.1% Triton X-100 in PBS) at 4° C until further processing for 
immunostaining [9]. Oocytes were incubated in a solution of mouse anti-tubulin 
(SIGMA T6074) in PBS with 1% BSA (dilution 1:50) at 4°C overnight. After extensive 
washing, the oocytes were incubated in a solution of INVITROGEN Alexa Fluor 488-
conjugated goat anti-mouse IgG (dilution 1:500 in PBS with 1% BSA) from for 1 h at 
room temperature in the dark, then washed again and mounted on slides in the anti-
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fade medium VectaShield. Oocytes were analyzed using the confocal laser scanning 
microscope (FLUOVIEW FV1000 model, Olympus, xxx) and in all lateral view plates 
the pole-to-pole tubulin spindle distance was measured (Figure 6.4).  
 Morphometric analysis of the meiotic spindle and plate was performed using 
ImageJ software and all measurements are expressed in microns. Plate diameter was 
calculated in polar view plates of oocytes treated as described above and expressed 
as the mean of 3 different diameters measurements (see Figure 6.4 A-B). 
 
6.2.4 Statistics 
 The analysis of inhibitor effects was carried out by evaluating 15-20 oocytes for 
each concentration/independent run. Experiments were repeated at least three times. 
Data were analyzed by one-way ANOVA followed by Tukey's multiple comparisons 
test or t-student test using Graph Pad Prism version 6.0 h accordingly to the 
experimental design. Data are presented as mean ± SEM. P values < 0.05 were 
considered as statistically significant. For each experiment, the specific test used is 
indicated in the figure legend.  
 
 
6.3 Results 
 
6.3.1 Dose response curve for Aglepristone and RU486 treatment during IVM 
 
 The administration of Aglepristone in increasing concentrations showed 
that the percentage of oocytes able to reach MII phase decreased significantly 
already after 1µM concentration of the inhibitor. At the same time, we observed 
an increase of the percentage of oocytes showing aberrant meiotic figures.  
Aberrant plates were mainly characterized by scattered chromatin or misaligned 
chromosomes and the absence of the polar body. No statistical differences were 
observed between standard control (basic maturation medium without DMSO) 
and solvent control (Figure 6.1 A).  
 Analogously, the administration of RU486 was effective in affecting the 
capability to reach MII-stage of meiotic division starting from 1 µM the percentage 
of oocytes able to reach MII-stage of meiosis decreased significantly. However, 
an increase of aberrant meiotic figures was observed only at the maximum 
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concentration tested (50µM) while the critical effect was a significant increase of 
oocytes arrested at MI stage of meiosis (Figure 6.1 B). 
 The following experiments were conducted evaluating the effects of using 
Aglepristone at a 1µM concentration.  
 
6.3.2 Comparison of the effect of AG205 and Aglepristone treatment during in 
vitro maturation  
 
 The results indicate that disrupting PGRMC1 function has a more 
detrimental effect on meiotic maturation. Indeed, inhibiting PGRMC1 using 
AG205 had a dramatic effect on the percentage of oocytes reaching MII meiotic 
stage, leading to a very high percentage of aberrant figures and confirming what 
was previously described [7]. By contrast, disrupting nPGR function with 
Aglepristone caused a lower percentage of aberrancies concomitant to a higher 
percentage of oocytes reaching MII phase (Figure 6.2). As to the aberrant 
figures, in AG205 treated oocytes half of the aberrancies was represented by 
double plates has already previously shown [7] (Figure 6.3), while in Aglepristone 
treated oocytes no double plates were detected and the aberrancies were 
represented by arrested or scattered plates (Figure 6.3). 
 Due to this difference, we decided to evaluate if the apparently normal MII 
plates in Aglepristone treated oocytes were equal to the control group from a 
morphological point of view.  
 
6.3.3 Effect of Aglepristone treatment on meiotic plate and tubulin spindle 
morphometry 
 Aglepristone treatment affected both MII plate diameter and tubulin spindle 
length; indeed, overall the diameter and the tubulin spindle were significantly 
bigger and longer compared to the control (Figure 6.4). 
 
 
6.4 Discussion  
 
 These data add new insights on P4 and their receptors role in oocyte 
meiosis. They suggest a possible P4 action mediated by both PGRMC1 and 
nPGR receptors affecting different meiotic maturation stages. Indeed, PGRMC1 
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might mediate an effect mainly on chromosome segregation since the effects of 
its inhibition strongly impairs MII plates morphology and maturation rate, while 
impairing nPGR has a mild effect on MII plate morphology and spindle formation 
that, however, could explain consequent reduced rate in blastocysts development 
observed in previous studies inhibiting P4 production with Trilostane and RU486 
nPGR inhibitor [1, 5]. 
  Moreover, rescue experiments with P4 after inhibition of nPGR confirmed 
the receptor was mediating a P4 signaling pathway [1]. While for PGRMC1, 
rescue experiments with P4 are still ongoing. However, our previous AG205 
studies showed that the detrimental effects of the inhibition on correct 
chromosome segregation were more pronounced on denuded oocytes compared 
to COC. This indicates that P4 could be part of the effect mediated by this 
receptor, since it is known that cumulus cells produce P4 during in vitro culture 
[10]. Therefore, we could assume that in the previous study [7] higher P4 
concentration was present in COC than DO culture. Thus, the presence of P4 in 
the COC culture could have attenuated the effect of AG205. This hypothesis is 
currently under investigation. 
 Since little is known on the mechanism of action of these receptors further 
studies are foreseen to understand P4 nPGR non genomic-mediated effect, since 
transcription in the oocyte is silenced, as well for PGRMC1 only some hypothesis 
have been proposed (see chapter 3.6).  
 In conclusion, P4 function in the ovary is complex and discordant or 
different results on its action could be due also to species-specific differences. 
Moreover, P4 levels and its binding affinity to each receptor, together with 
different expression patterns of its receptors in the follicle might be responsible 
of divergences in its action. However, the growing evidence of its role during 
oocyte maturation deserves more investigations.  
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6.5 Figures 
 
 
 
 
 
 
Figure 6.1 Dose response curve for Aglepristone treatment (A) and RU486 treatment 
(B) on meiotic progression. Graphs show the percentage of oocytes at each stage of 
the first meiotic division and of aberrant meiotic figures.  
 
 
 
 
 
 
 
Figure 6.2 Effect of AG205 and Aglepristone treatment during in vitro maturation 
showing the percentage of oocytes reaching MII phase and oocytes showing aberrant 
plates. a,b,c indicates significant difference (one-way ANOVA followed by Tukey's 
multiple comparisons test, P < 0.05). 
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Figure 6.3 
A. Graph showing distribution of different types of aberrancies in AG205 and 
Aglepristone treated oocytes expressed on the total of aberrancies.  
B. Representative images of aberrant meiotic figures in AG205 and Aglepristone 
treated oocytes showing an oocyte with a MII plate with I polar body (a), a double MII 
plate (b), a large plate with scattered chromatin (c) and an oocyte with DNA clumps 
scattered within the ooplasm (d). Scale bar is 10 µm. 
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Figure 6.4 Sample figures for plate diameter and spindle length measurement. 
Representative images showing tubulin (green) and DNA (blue) in MII oocytes after in 
vitro maturation. The tubulin image (A) shows the axis used for spindle length 
measurement in lateral view, while polar view plates (B) were used for diameter 
measurements calculating the media of the 3 axes shown.  
The bar graphs represent the measurement of the spindle lenght in MII-stage oocytes 
after in vitro maturation (mean± s.e.m.) (C) and of the spindle diameter (mean± s.e.m.) 
(D). a,b indicate significant difference (unpaired t-test, P < 0.05). 
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7. Characterization of Progesterone Receptor Membrane Component 1 
localization and putative function in the nucleolus of bovine granulosa 
cells and oocytes 
 
 
 
Foreword 
 
 
This chapter is a paper that has been accepted pending revision in Reproduction. In 
the meantime, additional experiments have been performed and the final accepted 
paper is attached in the appendix. 
Terzaghi L., Luciano AM., Chediek Dall’Acqua P., Modina SC., Peluso JJ., Lodde V. 
 Characterization of Progesterone Receptor Membrane Component 1  
 localization and putative function in the nucleolus of bovine granulosa cells and 
 oocytes.  Reproduction 		
 In this paper, we evaluated the role of PGRMC1 in a specific nuclear 
compartment, the nucleolus, both in somatic cells and in the oocyte to unravel one of 
its possible mechanisms of action. The localization of PGRMC1 has already been 
described in both nucleolus of somatic cells and in the zygote, while we evaluated 
through immunofluorescence its localization in a primary cell line of bovine granulosa 
cells and in growing and fully grown oocytes and its colocalization with the major 
nucleolar protein, nucleolin. Moreover, in somatic cells we assessed their functional 
relationship using RNAi technique to downregulate PGRMC1 expression. Indeed, 
besides its well-known role in ribosome subunits production, the nucleolus is also 
involved in cell cycle regulation determining protein modifications such as sumoylation 
and phosphorylation, sequestrating specific proteins or stabilizing p53 to arrest cell 
cycle after stress stimuli to the cell. While in the oocyte it completely disassembles 
during meiosis but still have an important role during previous oocyte growth and 
reassembles in early embryogenesis. 
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7.1 Abstract 
 Progesterone Receptor Membrane Component-1 (PGRMC1) is a highly 
conserved multifunctional protein that is found in numerous systems, including the 
reproductive system. Interestingly, PGRMC1 is expressed at several intracellular 
locations, including the nucleolus. The aim of this study is to investigate the functional 
relationship between PGRMC1 and the nucleolus. Immunofluorescence experiments 
confirmed PGRMC1’s nucleolar localization in bovine granulosa cells (bGC) and 
oocytes. Additional experiments conducted on bGC revealed that PGRMC1 co-
localizes with nucleolin, a major nucleolar protein. Furthermore, small interfering RNA 
(RNAi) mediated gene-silencing experiments showed that when PGRMC1 expression 
was depleted, nucleolin translocated from the nucleolus to the nucleoplasm. Although 
PGRMC1 influenced the localization of nucleolin, a direct interaction between these 
two proteins was not detected using in situ proximity ligation assay.  This suggests the 
involvement of additional molecules in mediating the co-localizaton of PGRMC1 and 
nucleolin.  Since nucleolin translocates into the nucleoplasm in response to various 
cellular stressors, PGRMC1’s ability to regulate its localization within the nucleolus is 
likely an important component of mechanism by which cells response to stress.  This 
concept is consistent with PGRMC1’s well-described ability to promote ovarian cell 
survival and provides a rationale for future studies on PGRMC1, nucleolin and the 
molecular mechanism by which these two proteins protect against the adverse effect 
of various cellular stressors.  
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7.2 Introduction 
 
 Progesterone Receptor Membrane Component 1 (PGRMC1) is a widespread 
and multifunctional protein that is highly conserved in eukaryotes. It belongs to the 
membrane associated progesterone receptor (MAPR) family and is expressed in 
several mammalian organs and tissues (Runko et al. 1999, Raza et al. 2001, Sakamoto 
et al. 2004, Bali et al. 2013a, Bali et al. 2013b), including those of the reproductive 
system (Zhang et al. 2008, Luciano et al. 2010, Aparicio et al. 2011, Luciano et al. 
2011, Keator et al. 2012, Saint-Dizier et al. 2012, Tahir et al. 2013, Kowalik et al. 2016). 
Specifically, granulosa and luteal cells of human, rodent, bovine and canine ovaries 
(Engmann et al. 2006, Peluso 2006, Aparicio et al. 2011, Luciano et al. 2011, Tahir et 
al. 2013, Griffin et al. 2014, Terzaghi et al. 2016) as well as oocytes express PGRMC1 
(Luciano et al. 2010, Luciano et al. 2013, Terzaghi et al. 2016). 
 Multiple functions are attributed to PGRMC1 (reviewed in (Cahill 2007, Brinton 
et al. 2008, Neubauer et al. 2013, Peluso & Pru 2014, Cahill et al. 2016, Ryu et al. 
2017)) as reflected by it being localized to numerous sub-cellular compartments.  As 
predicted by the presence of a transmembrane domain, PGRMC1 localizes in several 
membranous compartments, such as the endoplasmic reticulum, the Golgi apparatus, 
the nuclear and plasma membranes, the endosomes, and the secretory vesicles 
(Meyer et al. 1996, Raza et al. 2001, Bramley et al. 2002, Hand & Craven 2003, Shin 
et al. 2003, Sakamoto et al. 2004, Min et al. 2005, Peluso et al. 2006, Zhang et al. 
2008, Neubauer et al. 2009, Ahmed et al. 2010, Roy et al. 2010, Wu et al. 2011, Xu et 
al. 2011, Mir et al. 2012, Mir et al. 2013, Thomas et al. 2014). Interestingly, PGRMC1 
is also detected in the nucleus (Beausoleil et al. 2004, Peluso et al. 2008, Zhang et al. 
2008, Ahmad et al. 2009, Peluso et al. 2009, Luciano et al. 2010, Peluso et al. 2010a, 
Peluso et al. 2012), specifically to the nucleolus (Ahmad et al. 2009, Luciano et al. 
2010, Boisvert et al. 2012, Thul et al. 2017)] http://www.proteinatlas.org]. This high 
compartmentalization suggests that at each site PGRMC1 participates in the control of 
precise cellular processes.  
 In order to shed light into the intricate story of PGRMC1’s biological significance, 
it is important to dissect the function of PGRMC1 at each sub-cellular compartment. 
To this end, we have started to address whether PGRMC1 has a role in regulating 
nucleolar function.  Although the nucleolus’ main function involves ribosome subunits 
production, recent advances describe it as a multifunctional subnuclear compartment.  
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It appears that the nucleolus is a dynamic structure, which disassembles during mitosis 
and responds to signaling events during interphase.  As such, it is involved in cell cycle 
control, especially regulating protein modifications such as sumoylation and 
phosphorylation or sequestrating specific proteins (Boisvert et al. 2007). Furthermore, 
it acts as a stress sensor mediating p53 stabilization in order to arrest cell cycle 
progression (Boisvert et al. 2007, Boulon et al. 2010).  Thus, the overall goal of the 
present study is to examine the role of PGRMC1 on nucleolar function, particularly its 
relationship with nucleolin (NCL), a well-characterized nucleolar protein (Boisvert et al. 
2007, Tajrishi et al. 2011).  
 
7.3 Material and methods 
 
7.3.1 Reagents 
 
 All the chemicals used in this study were purchased from Sigma-Aldrich (St. 
Louis, MO) except for those specifically mentioned. Gene silencing was performed by 
using the Stealth RNAi™ siRNA technology from Life Technologies as previously 
described (Terzaghi et al. 2016) using PGRMC1 Stealth RNAi (PGRMC1 RNAi: (RNA)-
GAG UUG UAG UCA AGU GUC UUG GUC U) within the coding region of the bovine 
PGRMC1 sequence (RefSeq: NM_001075133). Negative control (cat n. 12935-200) 
was chosen among the Stealth RNAi negative control (CTRL RNAi) duplexes available 
from Life Technologies, designed to minimize sequence homology to any known 
vertebrate transcript. Primary antibodies used in this study are listed in Table 7.1.  
 
7.3.2 Sample collection 
 
Bovine samples: 
Ovaries from Holstein dairy cows were recovered at the abattoir (INALCA S.p.A., 
Ospedaletto Lodigiano, LO, IT 2270M CE, Italy) from pubertal females subjected to 
routine veterinary inspection and in accordance to the specific health requirements 
stated in Council Directive 89/556/ECC and subsequent modifications. Ovaries were 
transported to the laboratory within 2 hours in sterile saline (NaCl, 9 g/l) maintained at 
26°C and all subsequent procedures, unless differently specified, were performed at 
35-38°C. Bovine granulosa cells (bGC) were collected as previously described 
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(Terzaghi et al. 2016). Briefly the content of 2-8 mm ovarian follicles, which typically 
contain fully-grown oocytes, was aspirated and cumulus-oocyte complexes (COCs) 
were collected and processed for further immunofluorescence analysis (see below). 
Remaining follicular cells were washed in M199 supplemented with HEPES 20 mM, 
1,790 units/L Heparin and 0.4% of bovine serum albumin (M199-D). The cell pellet was 
re-suspended in 1ml of Dulbecco’s modified growth medium supplemented with 10% 
of bovine calf serum, 100 U/ml penicillin G, 100 µg/ml, Streptomycin and Glutamax 
100U/ml (Gibco). The cell suspension was plated in a 25 cm2 flask with 6 ml of growth 
medium and incubated in humidified air at 37°C with 5% CO2. After 24 hours cells were 
gently washed with PBS and the growth medium was changed. Cells were incubated 
until confluence, then collected after trypsinization and re-plated according to the 
experimental design (see below). 
 Oocytes in their growing phase, characterized by a diffuse filamentous pattern 
of chromatin in the nuclear area and the presence of an active nucleolus were collected 
as previously described from 0.5 to <2 mm early antral follicles by rupturing the follicle 
wall under the stereomicroscope (Lodde et al. 2008); Both COCs collected from 0.5 to 
<2 mm and 2-8 antral follicles were mechanically denuded using the vortex and fixed 
for further immunofluorescence analysis. 
 
7.3.3 RNAi treatment 
 
 RNA interference (RNAi) experiments on bGC were conducted as previously 
described (Terzaghi et al. 2016). Cells were plated in a total number of 2 X 105 bGC 
cells in 2 ml of medium on cover glasses in 35-mm culture dishes and incubated in 
humidified air at 37°C with 5% CO2. After 24 h, cells at 50-70% of confluence were 
transfected with 6 µl of 20 µM PGRMC1 Stealth RNAi or CTRL RNAi combined with 
10 µl of Lipofectamine RNAi MAX (Life Technologies) in a final volume of 2 ml 
OPTIMEM (Life Technologies), according to the manufacturer protocol, and cultured 
for 48 h.  
 
7.3.4 Western blot analysis  
 
 The levels of PGRMC1 protein expression in CTRL and PGRMC1 RNAi treated 
bGC were assessed by Western blotting assay as previously described (Terzaghi et 
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al. 2016). PGRMC1 or CTRL RNAi treated bGC were lysed in 
radioimmunoprecipitation assay (RIPA) buffer [50 mM Tris-HCl (pH 7.4), 150 mM 
NaCl, 1 mM EDTA, 1% Nonidet P-40 (NP-40), and 0.25% sodium deoxycolate], 
supplemented with protease inhibitors and phosphatase inhibitors. All procedures were 
conducted on ice. Total amount of protein was determined using the Qubit® Protein 
Assay Kit and Qubit® fluorometer (Thermo Fisher Scientific). 20 µg of total protein/lane 
were used for Western blottings. After the run, samples were transferred to 
nitrocellulose membrane (Bio-Rad), which was then incubated with 5% dry milk powder 
in TBS containing 0.1% tween (TBS/T) for 2 hours at room temperature. PGRMC1 
immunodetection was conducted using the rabbit polyclonal antibodies (see table 7.1) 
in 5% dry milk TBS/T. PGRMC1 was revealed using a stabilized goat anti rabbit IgG 
peroxidase conjugated antibody and detected using the Super Signal West Dura 
Extended Duration Substrate (Thermo Fisher Scientific). The nitrocellulose membrane 
was stripped in stripping buffer (100 mM 2-mercaptoethanol, 2% SDS, and 62.5 mM 
Tris-HCl [pH 6.7]) at 50°C for 30 min and re-probed with the anti beta tubulin antibody 
at dilution 1:1000, which was revealed using a stabilized goat anti mouse IgG 
peroxidase conjugated antibody as loading control.  
 
7.3.5 Immunofluorescence 
 
 Immunofluorescence staining was performed on bGC as previously described 
(Lodde & Peluso 2011, Terzaghi et al. 2016). Briefly, cells were fixed in 4% 
paraformaldehyde in PBS for 7 minutes and permeabilized with 0.1% triton-X in PBS 
for 7 minutes. Samples were blocked with 20% normal donkey serum in PBS and 
incubated overnight at 4°C with the rabbit anti PGRMC1 antibody (see table 7.1). 
Double immunostaining was performed on bGC by incubating the samples with the 
rabbit anti PGRMC1 or the mouse anti NCL antibodies or a combination of the two. 
After incubation with secondary antibodies for 1 h at room temperature, samples were 
washed and finally mounted on slides in the antifade medium Vecta Shield (Vector 
Laboratories) supplemented with 1 µg/ml 40,6-diamidino-2-phenylindole (DAPI). 
Immunofluorescent analysis on bovine oocytes were performed as previously 
described (Luciano et al. 2010) on 4% paraformaldehyde fixed oocytes. 
Immunofluorescent staining was performed as described for bGC with the exception 
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that oocytes were fixed for 30 min at room temperature followed by 30 min and 
permeabilized with 0.3% Triton-X 100 for 10 minutes.  
 bGC and oocytes were analyzed on an epifluorescence microscope (Eclipse 
E600; Nikon) equipped with a 40 X and a 60X objective, a digital camera (Nikon digital 
sight, DS-U3) and software (NIS elements Imaging Software; Nikon). 
Immunofluorescence negative controls, which were performed by omitting one or both 
the primary antibodies, did not show any staining under the same exposure settings. 
Images that were used for image quantification analysis were captured under the same 
settings. 
 
7.3.6 In situ Proximity Ligation Assay (PLA) 
 
 In situ Proximity Ligation Assay (PLA; Duolink® SIGMA) was used to assess 
the interaction between PGRMC1 and nucleolin in bGC following following the 
manufacturer protocol. Primary antibodies for PGRMC1 and nucleolin were the same 
used for immunofluorescence, while anti-rabbit PLUS and anti-mouse MINUS PLA 
probes were used as secondary antibodies. Negative controls were performed omitting 
one of the two primary antibodies. Cells were mounted with Duolink mounting medium. 
 
7.3.7 Image analysis 
 
 Quantification of Fluorescent Intensity (FI) signal was performed using the 
ImageJ software (https://imagej.net). The nucleolar signal of PGRMC1 in bGC was 
quantified calculating the integrated density of PGRMC1 signal selecting the whole 
PGRMC1 positive areas in the nucleus of a total of 50 cells for each treatment (CTRL 
RNAi and PGRMC1 RNAi treated cells) at 48 h after RNAi treatment. Data were polled 
and the mean FI of the CTRL RNAi treated group was set at 100%. FI values of the 
CTRL RNAi and PGRMC1 RNAi treatments were expressed as a percentage of the 
mean CTRL RNAi value. For image quantification of the NCL nucleolar and 
nucleoplasmic signals, threshold was selected by choosing a cutoff value such that all 
the nucleolar areas with an intense NCL signal within each cell. Then, the NCL total 
nuclear FI was assessed by selecting the whole nuclear area and calculating the 
integrated density of the corresponding regions of interests (ROI) of a total of 50 
randomly selected nuclei in CTRL RNAi and PGRMC1 RNAi treated cells. The NCL 
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nucleolar signal was calculated by analyzing the integrated density of the threshold 
area in each nucleus, while the NCL nucleoplasmic signal was calculated by 
subtracting the total nucleolar FI to the total nuclear FI of each nucleus. Data were 
polled and the mean nucleolar and nucleoplasmic NCL FI of the CTRL RNAi treated 
group were set at 100%. FI values of the CTRL RNAi and PGRMC1 RNAi treatments 
were expressed as a percentage of the mean CTRL RNAi value. Background signals 
did not change significantly among treatments 
 
7.3.8 Statistical analysis  
 
 Experiments were run in triplicate, unless otherwise specified. All statistical 
analysis was done using Prism software (GraphPad Prism v. 6.0e, La Jolla, CA, USA). 
Data from the replicate experiments were pooled and the data expressed as a mean ± 
SEM. Student’s t test was used to determine differences between two groups.  
 
 
7.4 Results 
 
7.4.1 PGRMC1 localization  
 
 Immunofluorescence analysis indicated that PGRMC1 localized to areas of the 
interphase nucleus that were not stained by DAPI. PGRMC1’s nuclear localization in 
bGC was the same regardless of which PGRMC1 antibody was used (Figure 7.1).  
However, nuclear staining for PGRMC1 with the Sigma Prestige antibody displayed a 
diffuse signal with the staining associated with DAPI-negative areas and only slightly 
more intense than that observed for the overall nucleus. In contrast, the non-DAPI 
stained areas within the nucleus were more intensely stained using the PGRMC1 
antibody provided by Proteintech (Figure 7.1).  These non-DAPI stained areas 
typically correspond to areas of the interphase nucleus where the nucleoli resided.  
 
7.4.2 PGRMC1 co-localization with nucleolin 
 
 To further characterize PGRMC1 localization in the nucleus, we evaluated its 
co-localization with the nucleolar marker, nucleolin (NCL), in both bGC and bovine 
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growing and fully-grown oocytes. Immunofluorescence data indicated that the two 
proteins co-localized in the nucleolus of bGC as shown in Figure 7.2; PGRMC1 signal 
appeared as a dotted pattern in the area corresponding to the nucleolus compared to 
NCL signal, which fully covered the nucleolus space (i.e. nuclear areas not stained by 
DAPI). Although co-localized, in situ proximity ligation assay did not detect an 
interaction between PGRMC1 and NCL, indicating the absence of a direct interaction 
between the two proteins in bGC (Data not shown).  
 In growing bovine oocytes, which are characterized by the presence of an active 
nucleolus (Fair et al. 1996, Lodde et al. 2008), NCL marked the nucleolus and showed 
a light diffuse staining pattern in the nucleoplasm as previously described (Fair et al. 
2001, Baran et al. 2004, Maddox-Hyttel et al. 2005). In particular, NCL nucleolar signal 
was intense and slightly more concentrated at the periphery of the nucleolus. In these 
oocytes PGRMC1 localized in the nucleolus showing a dotted staining pattern, similar 
to that observed in bGC nucleoli (Figure 7.2). In fully-grown oocytes (Figure 7.2), 
which typically displayed inactive nucleolar remnants (Fair et al. 1996, Lodde et al. 
2008), NCL was mainly dispersed in the nucleoplasm with a faint staining in the 
nucleolar remnants as previously described (Fair et al. 2001, Baran et al. 2004, 
Maddox-Hyttel et al. 2005). In these oocytes PGRMC1 concentrated in one or multiple 
dots where it co-localized with NCL. 
 
7.4.3 Assessment of PGRMC1 and nucleolin functional interaction  
 
 In order to establish the possible functional relationship between PGRMC1 and 
NCL, we silenced PGRMC1 expression in bGC by using RNAi. The RNAi protocol was 
previously validated by quantitative reverse transcriptase-polymerase chain reaction 
(qRT-PCR) showing a significant reduction of PGRMC1 mRNA levels compared to 
CTRL RNAi treated group (Terzaghi et al. 2016).  The decline in PGRMC1 expression 
after 48h PGRMC1-RNAi treatment was confirmed by Western blot analysis, 
regardless of which PGRMC1 antibody was used.  As shown in Figure 7.3A, PGRMC1 
was present in multiple bands, whose intensity decreased after 48h of PGRMC1 RNAi 
treatment. Moreover, quantification of PGRMC1 nucleolar immunofluorescent signal in 
PGRMC1 and CTRL-RNAi treated bGC revealed an approximate 40% decrease in 
PGRMC1 abundance in the nucleolus, which also gives confirmation of the specificity 
of PGRMC1’s nucleolar localization (Figure 7.3B and 7.3C). 
		 94	
 In order to assess the putative functional relationship between PGRMC1 and 
NCL, the effect of depleting PGRMC1 on the localization of NCL was evaluated. As 
shown in Figure 7.4, when PGRMC1 was depleted, a significantly higher quantity of 
nucleolin was present in the nucleoplasm when compared to the CTRL-RNAi treated 
group.  
  
		 95	
7.5 Discussion  
 
 The present findings demonstrate that PGRMC1 localizes to the nucleolus of 
both bovine granulosa cells and oocytes, suggesting that PGRMC1 has a role in 
regulating the function of the nucleolus of these two cell types.  The prominent 
nucleolar localization of PGRMC1 as revealed using the Protein Tech antibody is 
consistent with investigations of non-ovarian cells that detect PGRMC1 within the 
nucleolus by either immunohistochemistry (http://www.proteinatlas.org) or mass 
spectrometric analysis (Ahmad et al. 2009, Luciano et al. 2010, Boisvert et al. 2012, 
Thul et al. 2017).  However, the rabbit polyclonal antibody to PGRMC1 provided by 
Sigma Prestige detects PGRMC1 not only within the nucleolus but also in other 
interchromatin regions that resemble the nuclear speckles (Spector & Lamond 2011). 
The reason for this discord likely relates to the two antibodies detecting different 
molecular weight forms of PGRMC1. Western blots using either the Proteintech or the 
Sigma Prestige antibody detect PGRMC1 as bands at ≈ 25 and ≈ 55 kDa, while the 
Sigma antibody also detects an additional band at 37 kDA and two bands greater than 
55 kDA.  All the bands detected by either antibody are specific since their intensity is 
decreased in PGRMC1 RNAi-treated cells.  The different size forms of PGRMC1 are 
due to dimerization and post-translational modifications such as phosphorylation and 
sumoylation (Neubauer et al. 2008, Peluso et al. 2010b, Peluso et al. 2012, Kabe et 
al. 2016). Therefore, it is not surprising that polyclonal antibodies obtained using 
different immunogens may preferentially recognize one or multiple forms of PGRMC1, 
which in turn might preferentially localize in different subcellular compartment. 
 Because the Proteintech antibody precisely localizes PGRMC1 to the nucleolus, 
it was used to determine whether PGRMC1 co-localizes with the nucleolar protein, 
NCL.  This approach reveals that PGRMC1 and NCL co-localize to the nucleolus in 
bGC.  Moreover, depletion of PGRMC1 results in NCL within the nucleolus 
redistributing to nucleoplasm in these cells. Thus, localization of NCL is likely 
dependent in part on PGRMC1. This observation is biologically relevant since NCL 
mobilization from the nucleolus into the nucleoplasm is induced by different types of 
cellular stress.  For example, heat shock, ionizing radiation, and hypoxia all promote 
the translocation of nucleolin into the nucleoplasm (Daniely & Borowiec 2000, Daniely 
et al. 2002). In particular, NCL redistribution is induced by heat stress in HeLa cells 
and accompanied by an increase in the formation of a complex between NCL and 
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Replication Protein A (RPA) (Daniely & Borowiec 2000), which exerts important 
functions during DNA replication (Iftode et al. 1999).  NCL-RPA interaction in turn 
strongly inhibits DNA replication, likely by sequestering RPA away from sites of 
ongoing DNA synthesis (Daniely & Borowiec 2000). Other studies in U2-OS and U2-
OS p53-depleted cells demonstrate that NCL redistribution occurs when stress is 
induced by γ-irradiation and treatment with the radiomimetic agent, camptothecin.  
Under these stress conditions, NCL binds p53, which facilitates its transit into the 
nucleoplasm (Daniely et al. 2002).  These stress-induced changes in NCL’s 
localization suggest that various stressors change PGRMC1 function, altering its ability 
to retain NCL, which allows NCL to transit to the nucleoplasm.  This concept merits 
further investigation.  
 Although PGRMC1 and NCL often co-localize to the same sub-region of the 
nucleolus of bGC, they do not seem to directly interact, since we were not able to 
detect a positive signal by means of PLA assay. This might suggest that their functional 
interaction could involve the participation of another yet to be identified protein or 
proteins. Interestingly a known PGRMC1 binding protein, Plasminogen Activator 
Inhibitor 1 RNA-Binding Protein (PAIRBP1) (Peluso et al. 2006, Peluso et al. 2008, 
Peluso et al. 2013) (also known as SERPINE1 mRNA Binding Protein 1), which is 
typically found in the cytoplasm, localizes to the nucleolus under specific experimental 
stress induced conditions in Hela cells, such as treatment with arsenite and the 
methylation inhibitor adenosine periodate (Lee et al. 2014).  Therefore, it is possible 
that PAIRBP1 competes with this putative intermediary protein for binding to PGRMC1.  
The stress-induced formation of the PGRMC1: PAIRBP1 complex could potentially 
interfere with PGRMC1’ ability to retain NCL within the nucleolus and account for the 
translocation of nucleolin from the nucleolus into the nucleoplasm under stress 
condition.   
 Finally, the present study reveals the relationship between PGRMC1 and NCL 
in bovine oocytes.  PGRMC1 is present in the nucleolus of growing oocytes and the 
signal is retained to some extent in the nucleolar remnants of fully-grown bovine 
oocytes. During growth, the oocyte’s nucleus is characterized by the presence of a 
diffuse filamentous transcriptionally active chromatin and by a functional fibrillogranular 
nucleolus, which is gradually disassembled forming the so called ‘nucleolar remnants’, 
along with the progressive inactivation of rRNA synthesis that occurs at the end of 
oocyte growth (Fair et al. 1996, Lodde et al. 2008). Ultrastructurally, the nucleolar 
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remnants appear as electron dense spheres often showing a semilunar fibrillar center-
like structures attached (Fair et al. 1996, Lodde et al. 2008). In bovine oocytes, proteins 
such as RNA polymerase I and UBF remain associated to the inactive nucleolar 
remnants, while others, such as NCL and nucleophosmin mostly disperse in the 
nucleoplasm (Fair et al. 2001, Baran et al. 2004, Maddox-Hyttel et al. 2005). Upon 
meiotic resumption and during oocyte maturation the nucleolar remnant further 
disassembles and nucleolar proteins are probably dispersed in the cytoplasm. After 
fertilization the so called ‘nucleolar precursor bodies’ (NPBs) appear as electron dense 
compact spheres in the male and female pronuclei reviewed in (Maddox-Hyttel et al. 
2005). The NPBs serve for the re-establishment of a functional fibrillogranular 
nucleolus, which in bovine occurs at the time of major embryonic genome activation 
(at the 8-16 cell stage). It has been proposed that proteins engaged in late rRNA 
processing of maternal origin, including NCL, are to some extent re-used for 
nucleologenesis in the embryo while others need to be de-novo transcribed before 
being incorporated in the nucleolus (reviewed in (Maddox-Hyttel et al. 2005)). In this 
scenario, PGRMC1 localization in growing and fully-grown oocytes and in the NPBs of 
bovine zygotes (Luciano et al. 2010) suggests a role in both the disassembly and the 
reassembly of the nucleolus during meiosis and early embryogenesis. Interestingly, in 
growing oocytes (as in bGC) PGRMC1 and NCL showed a different localization 
pattern, with PGRMC1 showing a dotted localization. A similar pattern in growing 
bovine oocytes has been reported for the RNA polymerase I-specific transcription 
initiation factor, Upstream Binding Factor (UBF) (Baran et al. 2004). In future studies, 
it will be important to assess whether a specific functional interaction between NCL or 
other nucleolar proteins and PGRMC1 exists during early embryonic development and 
thereby influences the embryogenesis.  
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7.6 Tables and Figures  
 
7.6.1 Tables  
 
Table 7.1: list of antibodies used 
 
Cell type Technique Primary antibody  Secondary 
antibody  
Bovine 
Granulosa 
Cells (bGC) 
Immunofluorescence - Rabbit polyclonal anti-
PGRMC1 (1:50; Protein 
tech, 12990-1-AP) 
- Rabbit polyclonal anti-
PGRMC1 (1:50; Sigma, 
HPA002877) 
- Mouse monoclonal anti-
nucleolin (1:2000; Thermo 
scientific, MA1-20800) 
 
- TRITC-labeled 
donkey anti-rabbit 
(1:100; Vector 
Laboratories, Inc.) 
- Alexa Fluor 488-
labeled donkey 
anti-mouse 
(1:1000;Life 
Technologies) 
Oocytes Immunofluorescence - Rabbit polyclonal anti-
PGRMC1 (1:200; Protein 
tech, 12990-1-AP) 
- Mouse monoclonal anti-
nucleolin (1:2000; Thermo 
scientific, MA1-20800) 
 
- TRITC-labeled 
donkey anti-rabbit 
(1:100; Vector 
Laboratories, Inc.) 
- Alexa Fluor 488-
labeled donkey 
anti-mouse 
(1:1000;Life 
Technologies) 
Bovine 
Granulosa 
Cells (bGC) 
In situ proximity 
ligation assay (PLA) 
- Rabbit polyclonal anti-
PGRMC1 (Protein tech, 
12990-1-AP -1:50) 
- Mouse monoclonal anti-
nucleolin (1:2000, Thermo 
scientific, MA1-20800) 
 
Anti-rabbit PLUS 
and anti-mouse 
MINUS PLA 
probes (Duolink® 
In Situ PLA®) 
Bovine 
Granulosa 
Cells (bGC) 
Western blot - Rabbit polyclonal anti-
PGRMC1 (1:200; Protein 
tech, 12990-1-AP) 
- Rabbit polyclonal anti-
PGRMC1 (1:50; Sigma, 
HPA002877) 
- Mouse monoclonal anti- 
beta tubulin (1:1000; 
Sigma, T8328) 
 
- Goat anti rabbit 
IgG peroxidase 
conjugated 
(1:1000; Thermo 
scientific) 
 
- Goat anti mouse 
IgG peroxidase 
conjugated 
(1:1000; Thermo 
scientific) 
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7.6.2 Figures 
 
 
 
 
 
 
Figure 7.1: PGRMC1 immunofluorescent localization (red) in bGC obtained using 
SIGMA Prestige (A) and the Proteintech (B) rabbit polyclonal antibodies. DNA is 
stained with DAPI (blue). Insets show a single magnified nucleus. Note that both 
antibodies show intense staining in DAPI negative areas (arrows).  
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Figure 7.2: PGRMC1 (red) and NCL (green) immunofluorescence localization in bGC, 
growing oocytes and fully-grown oocytes. DNA is stained with DAPI (blue). Merged 
images shows partial PGRMC1-nucleolin co-localization (yellow). Insets represent 3X 
magnification. 
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Figure 7.3: Effect of PGRMC1 RNAi mediated gene silencing on PGRMC1 expression. 
(A) Representative Western blotting analysis showing PGRMC1 protein levels in 
PGRMC1 and CTRL-RNAi treated bGC after 48 h of treatment using the SIGMA 
Prestige and the Proteintech rabbit polyclonal antibodies. Beta tubulin was used as 
loading control. (B) Representative images showing PGRMC1 immunofluorescent 
staining in PGRMC1 and CTRL-RNAi treated bGC. (C) Graph showing analysis of 
PGRMC1 immunofluorescence intensity in the nucleolus of PGRMC1 and CTRL-RNAi 
treated bGC after 48h of treatment; * indicates significant difference (t-test, p<0.05). 
  
		 102	
 
 
 
Figure 7.4: Effect of PGRMC1 RNAi mediated gene silencing on NCL localization. (A) 
Representative images showing NCL immunofluorescent staining in PGRMC1 and 
CTRL-RNAi treated bGC; note the increased nucleoplasmic signal in PGRMC1 RNAi 
treated cell. (C) Graph showing analysis of PGRMC1 immunofluorescence intensity in 
the nucleoplasm of PGRMC1 and CTRL-RNAi treated bGC after 48h of treatment; * 
indicates significant difference (t-test, p<0.05).  
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8. PGRMC1 expression in canine mammary tumors: a preliminary study 
 
 
 
 
 
 
 
Foreword 
 
 
The preliminary data of this project were presented at the 37th National Congress of 
the Italian Society of Histochemistry - Taormina 22-23 Settembre 2017.  
 Terzaghi L., Banco B., Groppetti D., Modina SC., Dall’Acqua PC., Giudice C., 
 Pecile A., Grieco V., Luciano AM, Lodde V. Progesterone Receptor Membrane 
 Component 1 (PGRMC1) expression in canine mammary tumors.  
 European Journal of Histochemistry, 2017; Vol. 61, No 2s, 11-12.  
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8.1 PGRMC1 and cancer: an overview 
 
 PGRMC1 is reported to be overexpressed in a wide range of tumors, compared 
to corresponding normal tissues. It was first discovered as a protein induced during 
dioxin-stimulated tumorigenesis [1] and is also part of a six-gene signature associated 
with nongenotoxic carcinogens [2]. Then it was found as upregulated, detected as 
protein or mRNA levels, in different tumors in humans including lung, thyroid, colon, 
sebaceous glands, oral, head and neck, bladder and reproductive system, such as 
ovary, cervix and breast cancers [3-10]. PGRMC1 was detected also in plasma [11] 
and serum [12] of patients with lung and renal cancer, respectively, in which its level 
was higher compared to healthy patients. Moreover, PGRMC1 levels correlate with 
tumor stage in ovarian cancer [13] and estrogen receptor status in human breast 
cancer [14, 15].  
 Knockdown experiments showed that PGRMC1 promotes tumor cell 
proliferation, resistance to apoptosis caused by chemotherapy, invasion and 
metastasis in different tumor cell lines [3, 13, 16]. Also in in vivo, mouse xenograft 
studies showed the role of this protein in increasing tumor growth, angiogenesis and 
metastasis [16-18].  
 PGRMC1 also regulates autophagy [19] and could be involved in a conserved 
hypoxic/anoxic response in human tumors, possibly involved in Warburg effect, since 
it is part of an expression profile associated with hypoxia in tumors [20] and its 
expression was induced in a hypoxic zone of comedo-type ductal carcinoma in situ 
(DCIS) [15]. This is likely a conserved function since also the yeast homologue, DAP1, 
is inducible by mevalonate pathway activation, leading to steroid synthesis, especially 
under hypoxic conditions [21]. 
 The precise mechanism of action of PGRMC1 in tumor biology is still not clearly 
understood, and it could involve interaction with different proteins and diverse 
pathways. Recently, Kabe et al. demonstrated that heme-dependent PGRMC1 
dimerization is essential for its link to EGFR that highly supports its role in cancer. 
Indeed, EGFR is a tyrosin kinase receptor that is fundamental in activating oncogenic 
signaling pathways in cancer cells. In particular, phosphorylation of EGFR in response 
to its ligand (EGF) and its downstream targets AKT and extracellular signal-regulated 
kinases (ERK) were reduced when PGRMC1 expression was depleted. What’s more, 
their study showed PGRMC1 heme-mediated dimerization was essential in promoting 
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tumor proliferation of HCT116 colon cancer cells in vitro and their metastasis to liver in 
vivo [22]. 
 Finally, Kabe group also demonstrated that in HCT116 colon cancer cell line 
PGRMC1 dimer promotes chemoresistance to erlotinib and doxorubicin, facilitating the 
degradation of the latter via its ability to bind CyP450s, in particular the CYP2D6 or 
CYP3A4, which facilitate doxorubicin metabolism [22]. This suggests that a similar 
mechanism of action could be involved also in PGRMC1 mediated chemoresistance 
to cisplatin previously described in triple negative breast cancer cell line, MDA-MB-231 
[17] and ovarian cancer cells [13]. 
Some studies also suggested PGRMC1 as a possible marker of breast cancer risk in 
women whose breast epithelium is over-expressing this protein, which is important for 
mediating the strong effect on cell proliferation of certain synthetic progestogens 
combined with estrogens in this cancer therapy [9, 23] (Figure 8.1). 
 
 
 
Figure 8.1 Schematic diagram showing PGRMC1 heme-dependent dimer formation 
and its role for its interaction with EGFR and cytochromes P450 leading to cell 
proliferation and chemoresistance in cancer cells. From [22]. 
 
 Still there is a lot to investigate on PGRMC1 involvement in cancer to confirm 
its role and its potential usefulness as diagnostic marker and/or target for therapy. 
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8.2 Introduction and aim of the study  
 
 
 Given recent studies on PGRMC1 role in cancer as a tumor biomarker and its 
role in cellular division as main theme of this thesis, we are interested to study its 
putative role in veterinary oncology. To our knowledge, in veterinary oncology 
PGRMC1 is only described in cattle bladder cancer, in which the protein is 
overexpressed in neoplastic tissue and in blood of tumor-bearing animals compared 
to healthy ones [10].  
 Therefore, the aim of this preliminary study is to investigate on PGRMC1 
expression in canine normal mammary gland and in mammary tumors. The study 
includes an immunohistochemical analysis of PGRMC1 expression and localization 
and a further evaluation of different PGRMC1 isoforms using Western blot in healthy 
and tumoral canine mammary tissue. 
 Canine mammary tumors (CMT) are the most frequent neoplasm in female dogs 
[24, 25]. Risk factors include genetics, obesity, exposure to hormones and age (middle 
aged and older animals) [24].  
 Histopathological examination is the gold standard for CMT diagnosis and no 
molecular biomarkers are currently routinely in use. Canine mammary tumors are 
characterized by a varied morphology, forming simple (only one cell type resembling 
epithelial luminal or myoepithelial cells), complex (malignant epithelial and benign 
myoepithelial components), mixed (malignant epithelial component and myoepithelial 
component together with benign mesenchymal component such as 
osseous/cartilaginous/adipose tissue), and mesenchymal tumors. Carcinomas are the 
most common malignant CMTs, together with benign mixed tumors [26, 27].  
 Clinical prognostic factors found to be most consistently associated with 
outcome include tumor size, lymph node status, and clinical stage, together with 
histological invasion and grade (of carcinomas) [24]. Therapy is mainly surgical 
through mastectomy [24].  
 Hence finding a good biomarker could be useful for better tumor typing and 
enhancing precise classification of CMT for a more accurate subsequent prognosis 
and therapy. 
 
 
		 112	
8.3 Material and methods 
 
8.3.1 Sample selection and collection 
 
 No animals were killed for this study. All samples were originally submitted for 
diagnostic purpose to the Diagnostic Service of Veterinary Anatomical Pathology, 
Department of Veterinary Medicine, University of Milan. 
 For the immunohistochemical analysis, samples of CMT were retrospectively 
selected from the department archive. The tumor subtypes and number of samples 
selected are summarized in Table 8.1.	The normal/hyperplastic tissue surrounding the 
tumor was considered as normal tissue for every sample submitted to 
immunohistochemistry. 	
 For the western blot analysis, fresh tissue biopsies were obtained from dogs 
undergoing mastectomy for the presence of CMT at the Department of Obstetrics and 
Gynecology - University of Milan. Tissue biopsies were taken before placing the 
mammary glands in formalin with a punch (3mm X 7mm, kai medical) and immediately 
processed (see paragraph 8.3.3). Since surgical therapy consists of unilateral 
mastectomy with the removal of the entire mammary chain, for these cases we 
obtained also biopsies of normal tissue from the first or second thoracic mammary 
glands, free from neoplastic nodules. These further cases were also included for the 
immunohistochemical evaluation of PGRMC1 expression. 
 A complete clinical record is available for all cases including histological 
diagnosis established by board-certified pathologists. 
 
8.3.2 Immunohistochemistry analysis 
 
 Immunohistochemical analysis was performed on formalin-fixed and paraffin-
embedded samples. Endogenous peroxidase activity was eliminated by incubation 
with 3% H2O2 in methanol for 45 min. Then sections were incubated with 10% normal 
goat serum, 0.3% Triton X-100 and 3% bovine serum albumin (BSA) in phosphate 
buffered saline (PBS) for 30 min to block non-specific binding of secondary antibody. 
Samples were then incubated overnight at 4°C with rabbit polyclonal anti-PGRMC1 
primary antibody (SIGMA, cat. HPA002877, dilution 1:200). 
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Primary antibodies were detected by using a biotinylated anti-rabbit IgG (Vector 
Laboratories cat. BA-1000) diluted 1:400 in PBS with 1% of BSA and detected with the 
Vectastain Elite ABC kit (Vectastain Elite ABC kit, Vector Laboratories). Finally, 
samples were incubated for 2 minutes with DAB substrate (DAB substrate kit for 
peroxidase, Vector Laboratories) for color development and then counterstained with 
Mayer's haematoxylin for nuclear staining. Bovine ovarian tissue was included as 
internal positive control, while negative controls were performed omitting the primary 
antibody. 
 Protein labeling was evaluated independently by 3 veterinarians and classified 
by a scoring including the percentage area of the tumor expressing PGRMC1 and the 
intensity of the staining as weak (A), moderate (B) and strong (C).   
 
8.3.3 Western blot analysis 
 
 Western blot analysis was performed as previously described [28]. Briefly, 
punch biopsies of tumor tissue and normal/hyperplastic tissue, taken from the thoracic 
mammary glands not affected by neoplasia, were obtained after surgery. Tissue was 
immediately homogenized and lysed in radioimmunoprecipitation assay (RIPA) buffer. 
Extracted proteins were quantified with QubitTM Protein Assay Kit and QubitTM 
fluorometer (Thermo Fisher Scientific). A total of 50 µg protein/lane for each sample 
were loaded and equal protein loading was verified by Ponceau staining. PGRMC1 
immunodetection was performed using rabbit polyclonal anti-PGRMC1 antibody 
(SIGMA, cat. HPA002877, dilution 1:500) or mouse anti-pan Cytokeratin AE1/AE3 
antibody (Novusbio, cat. NBP2-29429, dilution 1: 400) overnight at 4°C. PGRMC1 and 
cytokeratins were revealed using a	 goat anti rabbit or mouse IgG peroxidase 
conjugated antibody antibodies (Thermo scientific, cat.32460-32430, dilution 1:1000) 
and detected using Clarity Western ECL substrate (BIORAD, cat. 170-5060). Negative 
controls were included omitting primary antibodies.  
 Relative amount of protein was quantified on scanned films using Image J 
software. Since PGRMC1 was expressed only in epithelial cells of mammary tissues 
we evaluated its levels relatively to the quantity of epithelial tissue in each sample. 
Hence, the intensity of all PGRMC1 bands was normalized for the intensity of the 
corresponding cytokeratins bands.  
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8.3 Results 
 
8.3.1 PGRMC1 expression and localization in canine mammary tissue and 
tumors 
 
 Canine normal mammary gland and hyperplastic areas, both surrounding the 
tumors and from tumor-free mammary glands, were consistently positive to PGRMC1. 
The protein was expressed in all epithelial cells of ducts and alveoli with a very strong 
(C) intensity of the staining (Figure 8.2 A).  
 In simple adenomas 80-100% of the tumor expressed PGRMC1 in the epithelial 
cells with a moderate-high intensity (B-C) (Figure 8.2 B). The same expression pattern 
was observed in complex adenomas and in some samples also mioepithelial cells were 
positive to PGRMC1 with a moderate intensity (B) (Figure 8.2 E) 
 In simple carcinomas, the expression pattern was the most heterogeneous; up 
to 60% of the tubulopapillary part of the tumor expressed PGRMC1 with a moderate 
to weak intensity (B-A). In solid parts of the tumor PGRMC1 was expressed only in 20-
30% of the area and the signal is weak (A), while other areas were negative for the 
protein (Figure 8.2 C-D). The same pattern was observed in the complex/mixed 
carcinomas samples (Figure 8.2 E).  
 The PGRMC1 expression patterns in canine mammary gland and CMTs are 
summarized in Table 8.2. 
 
8.3.2 PGRMC1 isoforms expression levels 
 
 Western blot analysis confirmed PGRMC1 presence both in normal and in 
neoplastic tissue. PGRMC1 monomer (25 kDa) was present in all samples, while its 
dimer was mainly expressed in normal/hyperplastic samples. An additional 37 kD band 
appears in only two tumoral tissues. The relative quantification of PGRMC1 presence 
relatively to epithelial cells, marked with a pan-cytokeratins antibody, revealed 3/5 
samples PGRMC1 expression as higher in normal tissue compared to neoplastic 
tissue, while 2/5 PGRMC1 expression was higher in the tumor (Figure 8.3). This could 
be explained, at least for tumoral sample n. 4, for the presence of epitheliosis foci. 
Indeed, epitheliosis is an intraductal hyperplasia, considered as a pre-neoplastic 
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lesion, in which PGRMC1 was expressed with very high intensity (C), so this could 
have determined the discordant result (Figure 8.4).  
 
8.4 Discussion 
 
 To the best of our knowledge our data showed for the first time PGRMC1 
expression pattern in canine normal mammary glands and in neoplastic mammary 
tissue. PGRMC1 expression is high in normal mammary gland and in adenoma, while 
it decreases in carcinoma neoplastic tissue, being less expressed in less differentiated 
parts of the tumor. This pattern mirrors the oestrogen α and progesterone receptors 
expression in CMT, which decrease with tumor malignancy [29]. 
 PGRMC1 presence and levels of expression were in part confirmed by western 
blot analysis. Recently, Kabe et al. described the importance of PGRMC1 dimer for 
PGRMC1 role in cancer, in particular in cell proliferation and chemoresistance, so the 
presence of the dimer band in canine normal tissue is controversial [22]. Nonetheless, 
normal/hyperplastic tissue could be actively proliferating hence this could explain the 
predominant presence of PGRMC1 dimer here rather than in tumoral tissue. 
 This preliminary study prompted us to continue investigate on PGRMC1 role in 
CMT including more tumor subtypes and increasing the number of cases. Moreover, it 
would be interesting to evaluate PGRMC1 specific subcellular localization with different 
techniques since, according to current hypothesis, PGRMC1 function could vary 
according to its localization in different systems. We should assess if there is any 
difference in PGRMC1 expression pattern consequent to differences in the hormonal 
mammary background in intact or ovariectomised dogs. 
 Finally, canine spontaneously occurring tumors are used as a model for different 
types of human tumors concerning study on tumor biology, diagnosis and development 
of new therapies [30, 31]. In particular, in human breast cancer (BC) there is limited 
literature on PGRMC1 immunohistochemical pattern of expression. In studies using 
the same antibody of ours [32], PGRMC1 is expressed by epithelial cells and in normal 
mammary gland it was moderately expressed, while in ductal carcinoma (the only 
subtype considered) its expression is moderate to strong (http://www.proteinatlas.org). 
This apparent difference between BC and CMT could be due to several factors; for 
example, different tumor subtypes considered, a complete different endocrinological 
background and single patient differences.   
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 Hence, the importance to study precise tumor subtypes that could be correctly 
compared is essential to draw any conclusion together with considering the wide 
individual variations.  
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8.5 Figures and tables 
8.5.1 Figures 
 
 
Figure 8.2 Representative images of PGRMC1 expression in canine mammary tumors.  
Scale bars are 50 µm. 
A. Normal mammary gland tissue. B. Simple Adenoma and normal surrounding tissue (arrow) 
C. Simple carcinoma, tubulopapillary part D. Simple carcinoma, solid part 
E. First image shows a complex adenoma, with also mioepithelial cells positive to PGRMC1 
(arrow). The other two images represent a complex carcinoma.   
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Figure 8.3  
A. Western blot analysis showing levels of PGRMC1 and CKAE1/AE3 in biopsies of 
normal and relative tumoral tissue.  
B. Graph showing PGRMC1 levels normalized to CKAE1/AE3 expression for each 
case. Tumor types details:  
Case 1. Complex carcinoma in mixed tumor. 
Case 2. Simple cribriform carcinoma 
Case 3. Carcinoma in mixed tumor 
Case 4. Simple solid carcinoma, cribriform, with epitheliosis 
Case 5. Tubular carcinoma, in part complex 
 
 
 
 
 
Figure 8.4 Example of epitheliosis foci (arrow) in sample 4 tumor. Scale bar is 50 µm.   
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8.5.2 Tables 
 
Table 8.1 Canine Mammary Tumor cases selected for immunohistochemical analysis 
for PGRMC1 expression. 
 
 
 
 
 
 
Table 8.2 Summary of PGRMC1 expression and corresponding scoring attributed for 
each tumor subtypes evaluated in the immunohistochemical study.  
 
 
Tumor subtype Percentage of PGRMC1 expression 
Intensity of PGRMC1 
staining 
 
Normal/hyperplastic mammary 
tissue 
 
100% C 
 
Simple adenoma/Complex 
adenoma 
80-100% B-C 
 
Simple carcinoma/Complex 
carcinoma 
 
Tubulopapillary: up to 60% 
Solid: 20-30% 
 
Tubulopapillary: A-B 
Solid: A to Negative 
staining 
  
Tumor subtypes Number of samples 
 
Simple Adenoma 7 
 
Complex Adenoma 5 
 
Simple Carcinoma 9 
 
Complex Carcinoma 5 
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9. General discussion and perspectives 
 
 
 During the course of this 3 years PhD program we have deepened previous 
studies conducted at the Reproductive and Developmental Biology Laboratory that 
consider PGRMC1 as one of the key factors involved in oocyte quality and follicular 
development, which are main systems involved in a successful reproductive outcome.  
 Among the multiple steps needed to reach the production of a viable embryo 
and consequent offspring, folliculogenesis and the production of a good quality female 
gamete is one of the crucial point, during which several defects that might occur could 
consequently affect reproductive efficiency. As described in the introduction chapter, 
nowadays infertility is a major issue in dairy cows that needs to be quickly solved as 
milk yield and production demand is constantly increasing and it is a major cause of 
economical loss besides impacting also on animal welfare.  
 Therefore, studying PGRMC1 role in bovine follicular system, according to its 
different subcellular localization, would deepen our knowledge on mechanisms that 
could impact mammalian follicle development and, subsequently, mammalian fertility. 
 Our studies give new insights into some aspects of the versatile PGRMC1 
protein in reproductive field.  
 Disrupting PGRMC1 function through gene silencing by RNAi or 
pharmacological inhibition lead to failure in both somatic cells and oocyte division, 
indicating PGRMC1 is required for this process given its localization at the mid-zone 
and mid-body of meiotic and mitotic spindles. Especially, our results showed the 
impairment of later stages of cell division impeding the correct completion of 
cytokinesis in somatic cells and polar body extrusion and metaphase II plate proper 
formation in the oocyte. These findings indicate for the first time the precise stage of 
cell division on which PGRMC1 might exerts its role. Moreover, our findings suggest a 
possible mechanism of action involving PGRMC1 interaction with AURKB in both 
systems, paving the way to perform more studies on the precise action of this protein 
in this particular subcellular site. 
 Moreover, we also addressed the hypothesis of PGRMC1 as a mediator of P4 
action comparing PGRMC1 and nPGR role in meiotic division. We demonstrated that 
inhibiting nPGR through Aglepristone and RU486 altered the progression of meiotic 
division affecting the proper spindle formation. Yet, the effects on the spindle are not 
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dramatic as what happens disrupting PGRMC1 function. This suggests that the two 
receptors might be involved in different stages of maturation and developmental 
competence of bovine oocyte mediating different P4 actions.  
 Since PGRMC1 function might depend on the specific subcellular domain in 
which it localizes, we gave our contribution showing its localization and possible role 
in the nucleolus of bovine granulosa cells and in the oocyte, which has been poorly 
investigated up to now. In granulosa cells PGRMC1 might have a functional 
relationship with nucleolin since our preliminary experiments showed their nucleolar 
colocalization and depleting PGRMC1 determines nucleolin shift into the nucleoplasm. 
This function is probably mediated by other proteins since the two proteins seem not 
to directly interact. While in the oocyte our localization studies suggested PGRMC1 
putative role in disassembly and reassembly of the nucleolus during meiosis and early 
embriogenesis, respectively.  
 Overall, our studies on bovine granulosa cells and oocyte could be relevant for 
further understanding PGRMC1 role as a key molecule in folliculogenesis and 
reproductive function.  
 Practically, the results of our studies could improve assisted reproductive 
technologies widely used in livestock; for example, through the identification of markers 
suitable to predict oocyte competence and its ability to give rise to healthy offspring or 
more basically to achieve a deeper insight in reproductive physiology.  Moreover, 
PGRMC1 is expressed also in human oocyte and ovarian cells and changes in its 
expression reflect impaired ovarian function. Indeed, in some women with polycystic 
ovarian syndrome [232] or premature ovarian failure [232, 233] reduced PGRMC1 
levels are present, while PGRMC1 overexpression was found in infertile patients 
undergoing gonadotropin-induced ovulation and in vitro fertilization [234]. Hence, the 
knowledge deriving from our studies could set the stage for further investigations also 
in human infertility and contribute to improve assisted reproductive techniques as well, 
helping in choosing the best gametes and conditions to gain the highest fertility rate 
with the lowest discomfort for the patient.  
 Finally, PGRMC1 role in granulosa cells division could be applied in a wider 
view of PGRMC1 function in somatic cells proliferation of other systems, in particular 
in the presence of diseases such as cancer. Indeed, oncology is another field that 
might benefit from these studies. Given its overexpression in many types of cancer and 
its emerging role in tumor proliferation and chemoresistance, PGRMC1 is more and 
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more studied as a putative biomarker and therapy target. So, besides PGRMC1 role 
in cell division in granulosa cell line, starting from our additional preliminary studies on 
PGRMC1 showing its presence and putative role in canine mammary tumors might 
unravel intriguing information on this very wide and contemporary topic. 
 
 We can conclude that our studies contribute to widening the notions about the 
complex understanding of the puzzling and intriguing PGRMC1 protein. 
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